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Abstract 
The most important factor in the successful outcome of the hematopoietic stem cell 
transplantation is that a patient and a donor are matched for the Human Leukocyte Antigens (HLA). 
Mismatching within HLA alleles (antigens) between a recipient and a donor increases the incidence 
and severity of an alloreactive immune response. Because of financial and technological limits, HLA 
data of donors are not complete, so we have to deal with fuzzy information. Therefore selection of 
the potentially best donor is not an easy task. Information and communication technologies play a 
key role in the donor search process in international registries of volunteer donors.  
This work focuses on the development of a modern search algorithm, one of the major 
challenges for donor registry computer systems. Our algorithm uses probabilistic matching that 
predicts, for each donor, the probability to be HLA allele identical to the patient. 
To achieve this goal, we have estimated HLA haplotype frequencies (population genetics 
models) for several populations, studied properties and reliability of these models, run simulations 
and validated the overall system. 
Abstrakt 
Úspěch transplantace krvetvorných buněk je nejvíce závislý na HLA genetické shodě mezi 
pacientem a dárcem. Případné neshody HLA alel (nebo antigenů) zvyšují riziko a závažnost selhání 
transplantace. Kvůli finančním a technologickým omezením, registry dárců nemají kompletní HLA 
data o všech dárcích, takže nemáme k dispozici přesné informace. Díky tomu není lehké vybrat 
nejvhodnějšího dárce. Informační a komunikační technologie hrají důležitou roli při hledání 
celosvětově nejlepšího dárce. 
Tato práce se zaměřuje na vývoj moderního vyhledávacího algoritmu, což je klíčová funkce 
počítačového systému registrů dárců krvetvorných buněk. Náš algoritmus používá 
pravděpodobnostní přístup, který pro každého dárce spočítá pravděpodobnost, s jakou tento dárce 
bude HLA shodný s pacientem. 
Abychom dosáhli tohoto cíle, tak jsme spočítali HLA haplotypové frekvence několika populací a 
vytvořili tak populační modely. Dále jsme studovali vlastnosti těchto modelů, jejich spolehlivost, 
provedli jsme simulace a nakonec jsme validovali celý systém. 
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1. Introduction 
Hematopoietic stem cell transplantation (HSCT) [1] (commonly referred to as bone marrow 
transplantation) is a medical procedure in the field of hematology and oncology. HSCT is the 
treatment of choice for people with hematopoietic malignancies (e.g. leukemia), bone marrow 
failure and certain types of cancer (e.g. lymphoma) which result in a compromised immune system. 
The principle is that intravenous infusion of stem cells collected from donor bone marrow, peripheral 
blood or umbilical cord blood is used to replace the hematopoietic functions of a patient with these 
conditions.  The most important factor in the successful outcome of HSCT is that the patient and 
donor are matched for the Human Leukocyte Antigens (HLA) [2]. Mismatching within HLA alleles 
(antigens) between a recipient and a donor increases the incidence and severity of an alloreactive 
immune response when transplanting hematopoietic stem cells. The level of the matching required 
varies with the source of stem cells used for HSCT. 
In most cases (in Europe) patients have no suitable HLA matched donor within their family, so 
physicians must activate a ‘donor search process’ by interacting with national and international 
donor registries who will search their databases for adult unrelated donors or cord blood units (CBU) 
[3].  
Information and communication technologies play a key role in the donor search process in 
donor registries both nationally and internationally. One of the major challenges for the donor 
registry computer systems is the development of a reliable search algorithm [4]. Our previous work 
[5] had focused on design and implementation of combinatorial approach. In principle, the algorithm 
compares patient with donors by counting all known and visible HLA mismatches. Implementations 
of such algorithms are commonly used, including the Bone Marrow Donors Worldwide computer 
system (BMDW) [6]. In 2011, the Information Technology (IT) working group of the World Marrow 
Donor Association (WMDA) has issued recommendations [7] that summarize current knowledge 
about implementation of this approach.  
Nowadays, there are more than 20 million stem cell donors and cord blood units available 
worldwide [6]. Due to character of HLA system, history of HLA typing techniques and limitation of 
resources, we do not have full information about HLA types of these donors. Search coordinators 
often see very long lists of partly HLA matching, partly HLA typed donors and they have to guess 
which donors should be selected for further HLA typing or testing. Limitation of resources (time and 
money) and risk of detours makes their choice tricky. An ‘expert system’ that would better lead the 
coordinator is needed to make faster and more accurate decisions.  
1.1 Goals of the work 
This work implements the probabilistic matching method that can predict donor data even if 
they are invisible or fuzzy at the moment. The main motivation [8] of the probabilistic matching is to 
help search coordinators to: 
 identify easy, difficult and (almost) futile searches 
 predict the level of patient-donor matching realistically achievable 
 speed up the donor search by choosing the most promising candidates and avoiding detours 
 make ultra-urgent searches feasible in spite of ambiguous or missing HLA data 
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In our previous work, we had used the combinatorial matching method that observes visible 
donor data and analyzes them, especially HLA mismatches. 
Currently, probabilistic matching systems are used in daily operations only by the biggest 
registries in the World. The Zentrales Knochenmarkspender-Register Deutschland (ZKRD) has 
pioneered this innovative technology and developed the OptiMatch® system [9] and the National 
Marrow Donor Program (NMDP) uses HapLogic™ system [10]. These registries have invested huge 
efforts into the development of the systems but their internals are not published. However, even if 
they publish them or provide them to smaller registries for free, it is not clear if others can use them 
and approximate local population by German or American models and what would be the reliability 
of such predictions.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Probabilistic matching system - structure of the work 
 
We will systematically implement new probabilistic matching system, see Figure 1. In order to 
do it, we have to answer these questions and satisfy the underlying goals: 
 How can we design and implement algorithm that creates population model? The 
population model will be represented by HLA haplotype frequencies estimates (HFE) and we 
will focus on the problem of estimation of HLA gene and haplotype frequencies of a human 
population. For this purpose, we want to use datasets of registries of unrelated 
hematopoietic stem cells donors that are the biggest available databases of HLA data for 
most of the populations in the world. These databases have been built and maintained for 
more than 10 years. HLA typing of d onors were determined by different typing techniques 
and a lot of data is missing. The combination with the complexity of HLA system and the size 
of these databases (up to millions of individuals) brings the problem to another level. 
Therefore the estimation of gene and haplotype frequencies in such conditions is a real 
challenge. 
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 What are the properties and reliability of the model (HFE) in general? Since we will 
approximate the local population by its stem cell donor registry datasets of different sizes 
and structures, we have to understand quality of the result. We need to study the 
dependency on the size of the population, genetic properties of the population, size of the 
sample (registry) and resolution of the donor typing. We are also limited by computational 
time. In practice, we have to deal with all these factors together. 
 How can we design and implement the probabilistic matching algorithm? We are looking 
for a solution even to countries for which it is not possible to create own model. The 
algorithm must be able to handle all types of cases, patient-donor pairs, even if the patient 
or the donor does not fit to our model (e.g. other ethnic). It has to be fast enough and give 
reliable results. 
 How can we validate the whole system? Can we apply it for all registries and populations? 
The whole system must be validated before its use. In some countries we can use historical 
data for validation, but in most countries, we don’t have enough data. Therefore we need to 
find novel method for validation, using simulation.  
HFEs are useful not only to support search for unrelated donors, but could be used in other 
applications, we will present some of them.  
 
1.2 Structure of the work 
The work is organized as follows: chapter 2 gives introduction to the HLA system, unrelated 
haematopoietic stem cell transplantation, stem cell donor registries and selection of unrelated stem 
cell donors. Chapter 3 focuses on the overview of computer algorithms in the search for unrelated 
stem cell donors.  
Chapter 4 is the overview of possible methods of HFE with focus on maximum likelihood 
function and its solution by the iterative Expectation-Maximalization (EM) algorithm. A method that 
can verify reliability of estimates is presented. 
Main part of the work starts by Chapter 5 that discusses the implementation of the HFE 
algorithm and its usage on datasets of stem cell donor registries – challenges, pitfalls and possible 
solutions. Chapter 6 gives new methods for testing of reliability of the HFE algorithm with stem cell 
donor registry datasets. Chapter 7 presents real results, using methods of chapters 5 and 6. 
Chapter 8 presents some applications of HFE, but we focus on the prediction of the HLA match 
in the chapter 9. Top-down design of the algorithm is described. We compare our approach with 
other implementations in the world (ZKRD, NMDP).  
Chapter 10 describes methods of validation of the HLA matching prediction algorithm and our 
results.  
Chapter 11 shows application of the algorithms and tools in daily operation of stem cell donor 
registries.  
Chapters 12 and 13 conclude the work.   
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2. HLA and haematopoietic stem cell transplantation 
This chapter gives introduction to the HLA system, unrelated haematopoietic stem cell 
transplantation, stem cell donor registries and selection of unrelated stem cell donors. 
2.1 Basic terms 
In the following text, we will use the terminology with the following meaning: 
 Locus – gene; HLA locus, e.g. DRB1 
 Antigen - one of the alternative versions of a gene at a given location (locus) along a 
chromosome; substances that are recognized by the immune system and induce an immune 
reaction. 
 Allele - one of the alternative versions of a gene at a given location (locus) along a 
chromosome; an individual inherits two alleles for each gene, one from each parent. If the 
two alleles are the same, the individual is homozygous for that gene. If the alleles are 
different, the individual is heterozygous. [9] 
 Haplotype – set of specific loci with antigen/allele designations. From each parent, a 
haplotype is inherited as unit [10]. 
 Genotype – particular combination of two multi-locus haplotypes [10]. 
 Phenotype – multi-locus genotype whose haplotype phase is unknown a priori [10]. 
 Linkage disequilibrium – association of alleles at two or more loci, combinations of alleles in 
a population that is more or less often than would be expected from a random formation 
of haplotypes from alleles based on their frequencies [11]. 
 
2.2 HLA system 
Human leukocyte antigen (HLA) genes are located on the short arm of chromosome 6. HLA 
genes are extremely polymorphic and play critical role in immune recognition and response. Each 
individual has two sets of genes; consequently, the combination of HLA markers of each individual is 
rare or almost unique in various populations.  
Polymorphism is beneficial for population studies, because it allows determination of genetic 
affinities among different populations. Haplotype studies are also important in complex research of 
genetic diseases, when we want to know association of diseases or risks with specific haplotypes. 
2.2.1 Human Leukocyte Antigen 
The major histocompatibility complex (MHC) [12] is a large genomic region or gene family 
found in most vertebrates. It is the most gene-dense region of the mammalian genome and plays an 
important role in the immune system, autoimmunity, and reproductive success. MHC genes are 
some of the most genetically variable coding genes in mammals. The proteins encoded by the MHC 
are expressed on the surface of cells in all jawed vertebrates, and display fragments of molecules 
from invading microbes or dysfunctional cells (e.g. tumor cells) to a particular type of white blood cell 
called a T cell that has the capacity to kill or co-ordinate the killing of the microbe, infected cell or 
malfunctioning cell. 
The best-known genes in the MHC region are the subset that encodes cell-surface antigen-
presenting proteins [12]. In humans, these genes are referred to as human leukocyte antigen (HLA) 
genes. 
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The most intensely-studied HLA genes (also called loci, sg. locus) are the nine so-called classical 
MHC genes: HLA-A, HLA-B, HLA-C, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, and HLA-
DRB1. In humans, the MHC is divided into three regions: Class I, II, and III. The A, B, and C genes 
belong to MHC class I, whereas the six D genes belong to class II. 
Besides being scrutinized by immunologists for its pivotal role in the immune system, the MHC 
has also attracted the attention of many evolutionary biologists, due to the high levels of allelic 
diversity found within many of its genes. Indeed, much theory has been devoted to explaining why 
this particular region of the genome harbors so much diversity, especially in light of its immunological 
importance. 
 
Figure 2: HLA complex on human chromosome 6 [13] 
 
2.2.2 Nomenclature of HLA System 
Nomenclature of HLA system is under responsibility of the WHO Nomenclature Committee 
[14]. Stem cell donor registries also follow the WMDA standards and recommendations [15]. Each 
HLA allele name has unique two, three or four field names. Fields are separated by colon (”:”). The 
length of the allele designation depends on the sequence of the allele and that of its nearest relative. 
All alleles receive at least a two field name, three and four field names are only assigned when 
necessary. 
The first field (number) describes the type, which often corresponds to the serological antigen 
carried by an allotype. The second field (number) is used to list the subtypes, numbers being assigned 
in the order in which DNA sequences have been determined. Alleles whose numbers differ in the first 
two fields must differ in one or more nucleotide substitutions that change the amino acid sequence 
of the encoded protein [16]. 
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Full code Abbreviation 
(unofficial) 
Description 
HLA-A A A means locus name (HLA gene) 
HLA-A2 A2 Serological antigen A2. Result of a serology typing 
method. 
HLA-A23 A23(9) or 
A23 
A23 is a split serological antigen of broad serological 
antigen A9. Result of serology typing method. 
HLA-A*02:XX A*02:XX or 
A*02 
Group of alleles (subtypes of antigen A2). Low 
resolution (LR) result of a DNA typing method. 
HLA-A*02:01 A*02:01 Allele A*02:01. An example of the high resolution 
(HR) results of a DNA typing method. 
HLA-A*02:01/02:02 A*02:01/02:02 or 
A*02:AB 
Group of two alleles A*02:01 and A*02:02. A*02:AB is 
the NMDP multiple allele code that represents the 
group. An example of intermediate resolution (IR) 
results of DNA typing methods. 
Table 1: Nomenclature of HLA System 
 
In this work, we will use both official and abbreviated nomenclature. 
 
2.2.3 Resolution of the HLA typing 
Based on the quality of HLA typing we can get HLA typing results of five different levels: 
 Broad serology antigen 
 Split serology antigen 
 Low resolution (LR) DNA typing 
 Intermediate resolution (IR) DNA typing 
 High resolution (HR) DNA typing. 
 
Broad and split serology antigen results are based on serology typing methods, while others 
are based on molecular biology typing methods. 
Low resolution means the identiﬁcation for the ﬁrst two digits of the HLA nomenclature, i.e. all 
alleles with the same first field. Intermediate resolution means selection of at least two allele codes, 
all belonging to the same serological antigen groups. High resolution typically means one allele 
designation with two or more fields (at least four digits). In some countries (e.g. Germany), multiple 
allele codes are still considered as high resolution, if all the alleles covered are identical over exons 2 
and 3 for HLA class I or over all of exon 2 for HLA class II. 
Nomenclature of locus names differs, if we speak about serology typing results or molecular 
biology (DNA) typing results. 
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Serology HLA-A HLA-B HLA-C HLA-DR HLA-DQ 
DNA HLA-A* HLA-B* HLA-C* HLA-DRB1 HLA-DQB1 
Table 2: Nomenclature of locus names of different typing methods  
 
In general, relation between typing results of different levels of typing of one individual is quite 
complex (see Table 3): 
 Broad serology antigen always represents a group of split serology antigens, so their relation 
is 1:n. E.g. broad serology antigen A9 represents group {A23, A24}. 
 LR DNA code represents a group of HR resolution DNA codes and every HR DNA code belongs 
exactly to one LR DNA code. I.e. A*01:XX represents group {A*01:01, A*01:01:01, 
A*01:01:02, …, A*01:02, A*01:03, …, A*01:20, …}. 
 Other relations are more complicated (m:n). IR DNA codes (also called NMDP codes or 
multiple-allele-codes) represent a group of HR DNA codes. I.e. A*01:AAXP represents group 
{A*01:02, A*01:08, A*01:14}. But a HR DNA code can belong to many IR DNA codes. I.e. 
A*01:01 belongs to A*01:AB, A*01:AC, A*01:AAJ, etc.  
 HR DNA typing result DRB1*11:16 can have corresponding split serology antigen DR11(5) or 
DR13(6) [17], but DR11(5) have many corresponding DNA typing results (DRB1*11:01, 
DRB1*11:02, …, DRB1*11:16, …, DRB1*11:60). 
 Other relations (m:n) are derived from previous facts. 
 
Resolution Split LR IR HR 
Broad 1:n m:n m:n m:n 
Split  m:n m:n m:n 
LR   m:n 1:n 
IR    m:n 
HR     
Table 3: Relation between levels of HLA typing (m:n – many to many, 1:n – one to many) 
 
2.2.4 Examples of HLA typing results 
Individual A 
HLA-A*01:01, 26:01 
HLA-B*38:01, 57:01  
HLA-C*06:02, 12:03  
HLA-DRB1*04:02,15:01 
HLA-DQB1*03:02,06:02 
 
(tested by molecular biology 
typing methods) 
Individual B 
HLA-A*03:01,32:BYJT 
HLA-B*35:01,38:01 
HLA-C*04:BRXU,12:03 
HLA-DRB1*01:01,13:03 
HLA-DQB1*03:01,05:01 
 
(tested by molecular biology 
typing methods) 
Individual C 
HLA-A1,9 
HLA-B17,40 
 
 
 
 
(tested by serology typing 
methods) 
Table 4: Examples of HLA typing results 
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2.3 Unrelated donor selection process 
Search for unrelated stem cell donors typically follows these steps [18] [19]: 
1. Patient HLA typing is determined. At least HLA-A, HLA-B, HLA-C, HLA-DRB1 and HLA-DQB1 
loci are tested. Sometimes also HLA-DRB3/4/5. Patient should be typed at intermediate or 
high resolution.  
2. Search coordinator runs the search algorithm in national and international registries.  
 
Figure 3: Example of donor search result [6] 
 
3. List of potential donors (see Figure 3) typically contains a lot of gaps (missing HLA typing 
results) or HLA ambiguities. Based on transplant protocol, consultation with transplant 
centres and local experience (or expert system predictions!), the search coordinator can 
select several (3-10+) potential donors for additional typing. These tests could be done by 
local or remote laboratories. Number depends on frequency of patient’s alleles & haplotypes 
(if rare, more donors are selected), clinical urgency (more urgent case requires simultaneous 
testing of several potential donors) and may be also limited also by patient’s financial 
situation (i.e. limited funding by healthcare insurance company) – requested services have to 
be paid by the applicant (hundreds of Euros). 
4. Some potential donors will be unavailable, so missing results will never be obtained. 
Contacting the donor, logistics of the blood sample and execution of the requested tests will 
take several weeks.  
5. Requested donor HLA typing results could show mismatch with the patient, so next rounds of 
additional typing procedure may be initiated. Common patient HLA types can usually find 
donor on first match run, less common may require a more sophisticated search using HLA 
expert help to prioritize donors/cords. Unfortunately, some searches are finished without 
finding a match. Then, other solution has to be found – physician has to change transplant 
protocol (e.g. mismatched donor or cord blood unit) or select non-transplant treatment. 
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6. If a suitable donor is found, the transplant centre – donor centre handshaking process is 
started (formal work-up requests, donor is examined, etc.), that may end up with the 
transplant operation. 
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3. Computer algorithms in the search for unrelated stem cell 
donors 
This chapter gives an overview of computer algorithms in the search for unrelated stem cell 
donors. 
3.1 Search algorithm 
The purpose of the donor search algorithm is to find and present a selected list of potential 
donors and/or CBUs, in which the most likely  an optimal stem cell source for the patient are sorted 
to the top of the list [7]. Selection and sorting criteria are based on HLA compatibility and may also 
take into consideration secondary preference criteria, such as CMV antibody status, gender and age. 
Basic requirements for the search system used by stem cell donor registries are: 
 Deterministic behavior that ensures the same results with the same input. This 
means, the algorithm has to reproduce exact decisions at every step. 
 Clear ranking order results. 
 Exhaustive - all donors available for transplant in the source database should be 
included in the search algorithm. Exceptions must be clearly indicated to the end-user. 
For example some algorithms exclude donors that are typed only at HLA-A and HLA-B. 
 Scalable - the system should be able to handle databases of varying size and type.  
 Fast – search algorithms are also used in user-interactive systems, so the results 
should be received in seconds. 
 Configurable – search coordinator must be able to define patient-donor HLA match 
criteria and secondary preference criteria (CMV status, gender, age). 
 Consistently matched [20] - The data presented should be uniformly matched as a set 
for a given instance of a patient search.  Different primary algorithms or matching 
criteria shall not be used within a single patient search.  
The search algorithm is usually implemented as the key component of the stem cell donor 
registry software system. It has several inputs and a single output.  The following input data are 
essential: 
 Patient’s data: HLA type (minimum HLA-A, HLA-B and HLA-DRB1 typing). 
 Patient’s match criteria (position and number of allowable mismatches) 
 Database of adult unrelated and cord blood units (CBUs) (optional) 
 HLA nomenclature code-lists 
 Allele and haplotype frequencies (optional, depending on type of the algorithm) 
The algorithm itself usually follows these steps: 
a. Pre-processing: fast pre-selection of donors based on predetermined  internal indices 
b. Processing: comparison of every (pre-selected) donor with the patient, calculation of match 
grades, matching probabilities and filtering 
c. Post-processing: linking corresponding donor/CBU details. 
The search output, which returns a sorted list of potential donors and CBUs can be presented either 
in the user interface, on a printed report or transmitted to other systems (EMDIS). The presentation 
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output may be calculated within in the search engine software. e.g. it is common practice to highlight 
patient-donor HLA mismatches. As well as match grade and matching probability this may require 
additional data extraction from internal information calculated during the execution of the 
algorithm. 
 
 
 
 
 
 
 
 
 
Figure 4: Basic concept of the donor search algorithm 
 
3.1.1 Patient’s data 
Patient’s HLA typing data must correspond to the valid HLA nomenclature and WMDA 
guidelines [15] and should be typed at the highest possible resolution, i.e. least intermediate 
resolution. According to some algorithms may return unexpected search results, if low resolution 
HLA typing data is provided. 
Example: B*35:76 has no mapping to ‘Unambiguous Serology’ [16], but is mapped to ‘Possible 
Serology’ B35 and B22. B22 is the broad HLA code with splits B54, B55 and B56. Therefore a patient 
carrying B*35:XX is a potential match with a donor carrying B*56:XX. Such a result is likely to be 
confusing for healthcare professionals. This problem would not appear if the patient was typed at 
higher resolution (the B*35:76 allele is excluded). An alternative solution would be to apply an 
exceptions or filter by application of additional criteria, e.g. matching probabilities with threshold (it 
is very unlikely the B*35:XX will become B*35:76). 
3.1.2 Patient’s match criteria 
Some algorithms have hard-coded or fixed match criteria, but more sophisticated search algorithms 
allow users to define matching preferences for each individual search. EMDIS Matching Preferences 
[21] define these criteria: 
 Counting method for mismatches: count graft-versus-host (GvH) mismatches only or host-
versus-graft (HvG) mismatches only 
 Maximum number of antigen/allele mismatches for adult donors 
 Maximum number of antigen/allele mismatches for CBUs 
 Maximum number of antigen/allele mismatches at loci A/A*, B/B*, C/C*, DR/DRB1*, 
DQ/DQB1* 
 Maximum age of the donor, gender matching, CMV matching 
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3.1.3 Database of donors and cord blood units (CBUs) 
Database of unrelated stem cell donors and CBUs should correspond to these requirements 
[20]: 
 Current - The data used by the algorithm should be up to date.   
 Detailed - The data presented should contain all relevant fields to the determination 
of match.  The set of data elements should be consistent amongst the registry 
community. 
 Integrated - The data presented should be considered as a set and should be available 
to the matching party as a part of a singular search event.   
 Recognizable - The data presented should uniquely reference individual sources using 
the identifier that is directly associated with the donor/CBU or would appear on any 
biological samples associated with the product.   
 Comprehensive - The data presented should represent a consolidated view of the 
inventory.  Uniform depth of access to all donors is needed. 
Good implementation of the donor database is essential for acceptable performance of the 
search algorithm. Not all database structures of HLA applications are suitable as the data source for 
the algorithm. 
Many small to middle size registries are co-located in a single centre with the HLA typing 
laboratory and there is a need for data integration of these two departments. It may seem the 
registry system stores and manages the HLA typing results in the same way as the HLA laboratory 
information management system (LIMS), and some registries have implemented such data storage. It 
is a mistake to use these in search algorithms. The main differences between registry database and 
HLA LIMS database are: 
 The registry system needs fast access to the most current and comprehensive HLA typing 
results, which does not always mean the last test typing. This may be combination of 
multiple tests performed in the past by multiple typing techniques. The registry system 
always needs access to the full set of all loci that should be stored at one place, while the 
HLA lab system order includes only requested tests and loci, so HLA typing results of an 
individual may be spread in multiple typing orders. 
 When the HLA lab supervisor approves the order results, it cannot be changed in the lab 
system. However, the registry system has to keep historical HLA typing results up-to-date 
according to the latest HLA nomenclature, so it needs to update them (deleted and renamed 
alleles, new HLA nomenclature). 
Database of donors/CBUs can simply be organized in a single relational database table. Even 
this may be problematic. A logical database approach is to organize HLA code-lists in separated tables 
(multiple-allele-codes, alleles, antigens and their relations) and define master-detail relationship 
between donor data and HLA codes. These systems have been implemented in some registries. The 
storage of donor record is using only primary keys of HLA codes (as foreign keys). The disadvantage 
of the master-detail storage is that retrieval of donor’s HLA typing is inefficient.  Often the solution 
for data retrieval in such a structure is cumbersome, because the database system has to join data 
(database natural join) from tens of tables .The advantage is easy manipulation with the properties 
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of HLA codes or even the renaming of HLA allele codes. But such operations are much less common, 
compared to data retrieval. 
3.1.4 HLA nomenclature code-lists 
In all cases, the algorithm has to recognize the description of HLA typing codes (e.g. multiple-
allele-codes) and relations between HLA codes, especially DNA to serology mapping. Some 
algorithms even use antigen recognition site matching, amino acid sequences or nucleotide 
sequences. It is recommended that code-lists and code attributes are downloaded from specialist 
reference web sites [16] and [22].  
Donors have been typed by various different typing techniques and many of them are 
registered with HLA serological assignments. The database of donors could be pre-processed, so all 
interpretations and mapping of HLA codes could be saved in advance, but generally, the patient’s 
HLA type is known only at the time of the search, so HLA nomenclature code-lists are needed. Of 
some concern is that a minority of  patients are still typed only by serologic typing techniques! This 
means that search algorithms must be capable of using these in the search process. 
3.2 Pre-processing 
Several variants of search algorithms are being used by stem cell donor registries. Selection of 
the algorithm is influenced by available resources, size of the donor database, availability of 
haplotype frequencies of the supported population(s), etc. We will discuss commonly used search 
algorithms. 
I. Simple pre-selection 
The goal of the algorithm is to find potential donors for one patient. The phenotype of the 
patient is compared with all donors phenotypes in the donor registry database that are ‘available’ for 
transplantation purposes (simple pre-selection). 
For every donor D in the database 
 Count Match Grade (patient P – donor D) 
 If the Match Grade is acceptable, store 
  data of donor D in the list of 
  potential donors of patient P 
 
This kind of algorithm can be used only for small to middle sized registries. Implementation 
enhancements can help to improve this situation. For example, increasing current capacities of 
server memories allows caching of all donors in the random access memory (RAM) of the server. The 
advantage of this algorithm is mainly in its simplicity and simple validation process. It also has very 
straightforward implementation of distributed or parallel computing. The drawback is the speed and 
memory limitation, especially where donor database is growing  
This algorithm could be extended to multiple patient searches [5] that might be useful, for 
example, for EMDIS repeat searches [21], when search results from several thousands of donors have 
to be generated and compared with previous results. Again, the list of all patients could be cached in 
the server memory with one additional loop. 
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For every donor D in the database 
 For every patient P in the database 
  Count Match Grade (patient P – donor D) 
  If the Match Grade is acceptable, store 
   data of donor D in the list of 
   potential donors of patient P 
II. Search determinants 
Databases from Registries and cord blood banks store the HLA types in many formats 
depending whether typing was by serology or by DNA-based methods. Registries must take these 
different assignments to create a match algorithm to search for a patient. This comparison is usually 
facilitated by the conversion of phenotypes to "search determinants" prior to development matching 
algorithms.  
The phenotype of the patient/donor is mapped to ‘Search Determinants’ (SD) [23] [24]. The SD 
is a data record, based on serological antigens, corresponding to the original HLA phenotype. For 
example, it might be a group of six HLA serologic-based assignments – three pairs for HLA-A, HLA-B 
and HLA-DRB1 loci. An individual can have multiple SDs. SDs are used as an index to select the set of 
matching phenotypes. Then, more precise match grades are counted and the list of donors is filtered.   
The main application of SDs is the speeding up of the match process by using SDs as keys 
values in conjunction with a database and a matching algorithm [25]. The main disadvantage is the 
need for regular checks and updates of SDs of all donors in the database, due to changes of donor 
data, HLA nomenclature updates and changes in the “DNA to serology” mapping. There are particular 
problems where there is no serological equivalent for a DNA allele. 
III. DNA matching only 
The National Marrow Donor Program (NMDP) in the United States has developed an algorithm 
[26] that does not use SDs for the initial matching step as this is done by directly comparing patient 
DNA type to donor DNA type. The algorithm is able to account for all serologic typing possibilities 
with the use of a special table called the "Serology to DNA Allele Table".  
3.3 Processing 
The key element of the processing step of the algorithm is the ‘match grade function’ that can 
compare data (HLA, ethnic group) of two individuals (usually patient and donor) and return their 
match grade and/or matching probabilities. The threshold function then filters out donors that do 
not match patient’s match criteria. 
 
 
 
 
 
Figure 5: Match grade function 
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Original versions of matching algorithms compared HLA typing only at HLA-A and HLA-B loci. 
DNA typing was not performed. Later generations added other loci, especially HLA-DRB1, but also 
HLA-C and HLA-DQB1. Today, some algorithms even use HLA-DRB3/4/5, HLA-DPB1 and other loci. 
Earlier versions of matching algorithms also used only serological assignments; DNA  typing   
either did not exist or was not taken into account. Later versions have converted DNA typing results 
into serological assignments or vice versa, so the algorithm has a uniform typing technique view on 
all donors. Current search algorithms use DNA typing results as much as possible and switch to 
serology comparisons only if DNA typing is not provided or if they want to refine DNA to serology 
mapping.  
The Information Technology (IT) Working group of the World Marrow Donor Association 
(WMDA) has issued two key resources that describe the correct handling of HLA data and key 
patient-donor matching procedures: 
 Framework for the implementation of HLA matching programs in hematopoietic stem cell 
donor registries and cord blood banks [7]. This article gives a bottom-up approach to the 
design of search algorithms: comparison of individual HLA codes, then HLA single-locus 
phenotypes and eventually HLA multi-locus phenotypes. 
 Guidelines for use of HLA nomenclature and its validation in the data exchange among 
hematopoietic stem cell donor registries and cord blood banks [15] 
A common mistake in the design of search algorithm is the violation of the rule 2.1 of the 
guidelines [15]: “Laboratories must assign DNA nomenclature to results obtained using DNA-based 
methods and serologic nomenclature to results obtained using antibody reagents.”. Some computer 
systems need to permanently store serology derived results of DNA codes, usually because of simple 
DNA-serology matching. However, the mapping should be done automatically by the system and not 
by the user. Derived serology values must be clearly distinguished from real serology results obtained 
using antibody reagents. Where mapping has changed, the registry system has to know if stored 
serologic results should be updated or not. Moreover, some alleles are mapped to multiple serology 
equivalents and the system has to take this into account. 
In addition to match grade, some information can be calculated. In these, the probability of 
HLA matching at the allele level based on local population haplotype frequencies in the underlying 
population can be calculated. Such prediction algorithm system has been developed and validated  
by the NMDP (HapLogicTM II) [27].  
The latest, state-of-the-art versions of search algorithms (OptiMatch®, HapLogicTM III) use these 
probability calculations to determine the rank order of HLA matches as the main searching and 
sorting criteria. 
3.4 Post-processing 
At this stage, the system retrieves corresponding donor details of all selected donors that will 
be displayed in the search results. If the matching probabilities are not used as the main sorting 
criteria, the search system can apply them at this stage (ProMatch [28], Hap-E [29] and EasyMatch 
[30]).  
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3.5 Validation of the search algorithm 
All implementations of the search algorithms need to be validated before being used. The 
WMDA Information Technology Working Group provides validation sets of patients and donors that 
are used for matching trials and comparison of results with expected outcomes [31] [7]. Algorithms 
that do not use simple pre-selection approach, but use more complex pre-selection, have to be 
validated for completeness. It is important not to miss any relevant donors in the pre-selection [7]. 
Validation of the processing phase, especially the match grade function, can be done by 
running several automated unit tests, addressing all kinds of matches and mismatches, exceptions 
and rare cases. Interfaces to software source code classes, modules or libraries are tested with a 
variety of input arguments to validate that the results that are returned are as expected [32].  
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4. Haplotype Frequencies Estimation 
This chapter gives an overview of possible methods of HFE with focus on maximum likelihood 
function and its solution by the iterative Expectation-Maximalization (EM) algorithm. A method that 
can verify reliability of the estimates is presented. 
4.1 Number of genotypes 
The number of genotypes ( jc ) leading to the j-th phenotype is a function of the number of 
heterozygous loci js : 
(1) 
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Example 1 
Assume the following phenotype of an individual ( 3js ): A1,2 B7,8 DR1,4 
Then all possible genotypes are ( 422 jc ): 
A1 B7 DR1 
A2 B8 DR4 
A1 B7 DR4 
A2 B8 DR1 
A1 B8 DR1 
A2 B7 DR4 
A1 B8 DR4 
A2 B7 DR1 
□ 
Only one of these jc genotypes is the proper one. 
 
4.2 Problem formulation 
Typing techniques allow the survey of many polymorphic loci, but do not allow distinguishing 
gametic phase of haplotypes. For heterozygous diploids the direct sequencing of the PCR 
(polymerase chain reaction) product results in the amplification of both alleles and does not allow 
resolving the haplotypes when the diploid individual is heterozygous at more than one locus. 
The data set consists of individuals (sample of a population) and their unphased HLA typing 
results at one or more loci.  
The goal is to find the best estimates of the haplotype frequencies in the population using 
only limited information included in the phenotype (unphased genotype) sample data.  
4.3 Methods 
The main methods of solution of the problem are: 
1. Family studies – adding some additional information. 
2. Remove heterozygous individuals – ignoring the problem. 
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3. Parsimony method – counting phase known individuals 
4. Two by two tables – solution only for two loci 
5. Bayesian methods  
6. Maximum likelihood approach 
 
4.3.1 Family studies 
Multi-loci haplotypes can be usually determined by additional genealogical study of the 
individual. [35] 
Family members of many individuals could not be reachable for tests. Therefore the family 
studies of all individuals in the data set are not possible. Moreover, to avoid redundant information 
and possible bias, some members of the families must be excluded from the data set, so the costs 
would be extremely high. This approach is not scalable for large data sets.  
 
4.3.2 Remove heterozygous individuals 
The easiest possibility would be to remove all heterozygous individual from the sample and 
keep only homozygous ones. Then calculate haplotype frequencies by direct counting.  
This approach is problematic, because it might lead to a bias. 
 
4.3.3 Parsimony method 
Clark’s algorithm [33] and its variation [34] start to examine complete homozygotes and single-
locus heterozygotes and creates list of haplotypes that must be present unambiguously in the 
sample. If such individual does not exist, then the algorithm cannot start. Then other individuals are 
screened for a possible occurrence of previously recognized haplotypes. For each positive 
identification, the complementary haplotype is added to the list of the recognized haplotypes, and so 
forth. Problems of the approach are: 
(a) homozygous individuals are not always present in stem cell donor registry databases or there 
can be only few of them;  
(b) the final result depends on the order of individuals in the sample as shown in [35]. 
(c) in the end there could remain unresolved individuals. 
 
4.3.4 Two by two tables 
The estimation method [34] [36] counts the phenotype frequencies of each antigen in the 
sample for both (two) loci and uses these to calculate the linkage disequilibrium of each haplotype 
consisting of two alleles i and j as follows: 
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in which a, b, c and d are the phenotype frequencies of the +/+, +/-, -/+ and -/- combinations of the 
allele in each haplotype and n is the sum of a, b, c and d. The haplotype frequency of allele i from the 
first locus and allele j from the second locus is then: 
 
jiijij ggDp   
where ig and jg are gene frequencies of allele i, resp. j.  
 
This method is computationally simple, but unfortunately it works only for two loci and gives 
worse results than maximum likelihood approach [34]. 
 
4.3.5 Bayesian methods 
The PHASE algorithm [37] threats haplotype configuration for each unresolved individual as an 
unobserved random quantity and aims to evaluate their conditional distribution, given a sample of 
unphased data. Goal of the Bayesian framework is to approximate posterior distribution of haplotype 
configurations f(G|P), where  
G = (G1, …, Gn) denote to unknown corresponding haplotype pairs (genotypes), n is number of 
individual in the sample and P = (P1, …, Pn) are known unphased phenotypes. The method 
implements Markov chain Monte Carlo (MCMC) methods (Gibbs sampling) to sample from f(G|P). It 
starts with random configuration G(0), repeatedly selects unresolved individuals at random and 
samples from their possible haplotype configurations, assuming all other individuals to be correctly 
resolved. Repeating this process enough times results in an appropriate sample from f(G|P). In other 
words, it constructs Markov chain G(0) , G(1), G(2),… with stationary distribution f(G|P) on the space of 
possible haplotype reconstructions. 
The output of the PHASE algorithm is haplotype frequency estimation and reconstruction of 
haplotypes of each individual in the sample. 
 
We have cooperated with Mr. Urban on his Master’s thesis [38] regarding the problem of 
haplotype frequency prediction and haplotype resolution using statistical methods in general, and 
specifically in the context of HLA data. Mr. Urban has proposed a new Bayesian approach that uses 
the available prior knowledge to solve this task. The algorithms has been compared with our  
approach (EM algorithm) and even though it gave worse results in terms of accuracy, its robustness 
in speed when faced with large datasets with missing or ambiguous information in principle allows 
for processing of register data on a massive scale. 
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4.3.6 Maximum likelihood approach 
Under of the assumption of the Hardy-Weinberg equilibrium [39] and random mating, the 
probability jP  of the j-the phenotype is given by the sum of the probabilities of each of the possible 
jc genotypes: 
(2)   
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where )( lkhhP is the probability that the i-th genotype is composed of haplotypes k and l: 
(3)  
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and ip denotes the frequency of the i-th haplotype ih in the population. 
The probability of a sample of n individuals, conditioned by phenotype frequencies 
mPPP ,,, 21   is given by the multinomial expression 
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where m denotes the total number of phenotypes and jn is the number of individuals carrying the j-
the phenotype observed in the sample: 
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Substituting equation (2) into equation (4), we obtain the probability of the sample as a 
function of the unknown the haplotype frequencies. Therefore, the likelihood of the haplotype 
frequencies given phenotypic counts is: 
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4.4 Solutions of maximum likelihood function 
Possible methods of solution of the maximum likelihood function are: 
1. Analytic solution [42] 
2. Genetic algorithms (own attempt) 
3. EM algorithm [43] 
 
4.4.1 Analytic solution 
We can logarithmize the equation (6) and get: 
(8)   
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where 1a is a constant incorporating the multinomial coefficient. 
The maximum likelihood estimates of haplotype frequencies could be, in principle, found 
analytically or numerically by solving a set of equations resulting from the 1h  partial derivatives 
equated to 0: 
(9) 






 m
j t
j
j
j
t
ht
p
P
P
n
p
L
1
1,,2,1,
log
   
However the nonlinearity of (9) and a large number of equations when practical data are 
analyzed (tens of thousands for real data) make this approach prohibitive. Moreover the h is often 
unknown a priori. 
Numerical methods must be used to solve these equations and find the maximum. Many numerical 
methods are sensitive to rounding errors and they are usually not able to prove that a particular 
solution is the global maximum. Procedures based on analytical solution are limited to a few loci and 
polymorphism.  
4.4.2 Genetic algorithms 
Maximum likelihood approach is an optimization problem, so we can consider genetic 
algorithms (GA) to solve it. Fitness function is very straightforward, because it is the Maximum 
likelihood function.  
But we are in troubles with the definition of GA-chromosome. It should store the result of the 
algorithm, which is the list of haplotypes and their frequencies. Maximal length of the list is mn 2 , 
where m is number of heterozygous loci in the sample ( jsm max ). Every item of this list 
(haplotype frequency estimation) is a real number (the frequency) and m loci with allele designations 
defining the haplotype. Each HLA locus can have approx. up to 1000 different alleles, so we can 
encode them to 10 bits. If we encode a real number to 32 bits (frequencies could be very small 
numbers) we get the size of the GA-chromosome to max. )3210(2  mn m . For real data (
610n  and 3m ) we get the GA-chromosome bigger than 0.5 MB which is not feasible for GA. GA 
could solve only small instances of the problem and is not applicable in our situation. 
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4.4.3 EM algorithm 
One of the most widely used methods of haplotype reconstruction is Expectation-
Maximalization (EM) algorithm, which estimates haplotype frequencies iteratively. Since we have 
used this approach as a basis of our solution, we will describe this algorithm in the following chapter. 
4.5 Expectation-Maximalization (EM) algorithm 
Association of haplotype structures and sample of unphased genotypes can be expressed by 
likelihood function (see also section 4.3.6). The relation (6) is complicated and cannot be maximized 
by standard techniques, as has been discussed before.  
The Expectation Maximalization (EM) algorithm was formalized by Dempster A.P. et al. in 1977 
[40]. Dempster has proven the monotone behaviour of the likelihood and derived the convergence of 
the algorithm. Its application to the problem of haplotype reconstruction was formulated in 1995 by 
several authors [10] [35] [41]. Since then the method and its properties were further analyzed by 
several studies [42] [43] [44]. They have shown it can be used for wide variety of population and 
data-set scenarios.  
 
4.5.1 Algorithm description 
The EM algorithm is an interactive method of computing sets of haplotype frequencies 
hppp ,,, 21  starting with arbitrary initial values
)0()0(
2
)0(
1 ,,, hppp  . These initial values are used to 
estimate genotype frequencies  lkhhP
~
 as if they were the unknown true frequencies (the 
expectation step). These expected genotype frequencies are standardized and used, in turn, to 
estimate haplotype frequencies pˆ at the next iteration (the maximization step), and so on, until 
convergence is reached. 
 
4.5.2 Initial conditions 
There are several possibilities of initializing the haplotype frequencies 
)0()0(
2
)0(
1 ,,, hppp   with 
respect to equation (7). They can be summarized as follows: 
 (IC1) All haplotypes are equally likely 
(10) h
h
t nt
n
p ,,2,1,
1)0(  .  
 (IC2) All possible genotypes of each phenotype are equally likely 
(11)   mj
c
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j
lkj ,,2,1,
1)0(  .  
 (IC3) Initial haplotype frequencies are chosen at random. 
 (IC4) All initial haplotype frequencies are equal to the product of the corresponding single-locus 
allele/antigen frequencies (complete linkage equilibrium). 
 (IC5) The input data influence the initial haplotype frequencies. 
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4.5.3 The expectation step 
 Estimation of genotype frequencies, given haplotype frequencies: 
(12) 
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4.5.4 The maximization step 
 Estimation of phenotype frequencies, given genotype frequencies 
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 Standardization of genotype frequencies 
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 A genotype has one or two specific haplotypes, so genotype frequencies can be used to estimate 
haplotype frequencies by direct counting of all occurrences of a haplotype within all sample 
genotypes. 
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where it is an indicator variable equal to the number of times haplotype t is present in the genotype 
i: 
(16) 
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4.5.5 The stopping criterion 
The stopping (convergence) criterion can be defined as: 
 (SC1) the relative difference between the consecutive ML function values is less than an arbitrary 
parameter 0 . 
 (SC2) the absolute value of difference between the consecutive ML function values is less than an 
arbitrary parameter 0  [43]. 
 (SC3) when the changes in haplotype frequency in consecutive iterations are less than an 
arbitrary parameter 0 : 
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4.6 Properties of EM algorithm 
Sample size 
As expected, the algorithm performs better for larger samples sizes, i.e. give better estimates, 
as shown in [10]. 
Multiple local maxima 
EM algorithm climbs the multidimensional likelihood surface, but there is no guarantee that 
the surface is convex, i.e. there is no proof for uniqueness of a likelihood function maximum, so the 
likelihood surface may have multiple local maxima [43]. 
To ensure finding global maximum likelihood, the EM algorithm should be started from several 
initial conditions [10]. 
 
Deviation from HWE 
Departure from HWE may be a substantial source of error, because the algorithm relies on 
HWE in its expectation step. However, deviation from HWE will not result in a significant 
differentiation in the haplotype frequency estimation [45]. Also linkage disequilibrium does not 
impact highly on the common haplotype frequencies [42]. 
 
Convergence speed 
Most studies confirm high convergence speed of EM algorithm, e.g. in less 20 iterations by [43] 
or in less than 50 iterations by [42]. 
 
Other properties that could be studies are: shape of log-likelihood graph, sensitivity to 
stopping criteria, LD and departures from HWE and sensitivity to different initial conditions. 
4.7 Reliability of haplotype frequency estimation 
There is no single measure of performance of EM algorithm, because there are many possible 
uses of it and the choice of a measure depends on the intended purpose [10]. Anyway some 
properties could be observed. 
 
4.7.1 Haplotypes with low frequency 
When we run haplotype frequency estimation algorithm, we might get list of tens of thousands 
of haplotypes, but some of them could have very low frequency (e.g.
50010ip ). The question is if 
these low frequencies are reliable or not. 
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We use similar approach as [46], which estimates the minimal registry size in order to calculate 
reliable haplotype frequencies. In our case, we have fixed size of the sample (registry) and we want 
to know the reliability of haplotype estimates. 
Reliable estimation of the frequency of a haplotype should be supported by at least one 
individual in the sample carrying the haplotype. If the frequency of i-th haplotype is ip  and the 
sample size is n, then the probability that the individual hasn’t the i-th haplotype is  21 ii pP  , 
because the individual has two haplotypes. The probability Q that at least one individual with i-th 
haplotype is found in n individuals is: 
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If we want to reach certain probability Q, we can fix it as constant and we get 
   ipnQ  1ln21ln  
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Table 5 shows examples of minimal reliable ip values for different n and Q values. 
 Q 
N 0.95 0.99 0.999 
210  210487.1   210276.2   210395.3   
310  310498.1   310300.2   310448.3   
410  410498.1   410302.2   410453.3   
510  510498.1   510302.2   510454.3   
Table 5: Minimal reliable value of haplotype frequency estimation. 
 
On the other hand, if a haplotype exists in the sample, then at least one individual has to carry it. 
Since number of haplotypes in the sample is 2n, the minimal frequency of any haplotype must be  
(20) 
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Combining these two approaches, we get 
(21) 
en
PQ
n
n
i
1
1
2
1
111
2







  
The calculated value of Q is 0.63 for all values of n mentioned in Table 5. 
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4.7.2 Lab-based verification of the EM algorithm 
Verification of the algorithm can be done by this scheme [42]: 
1. Generate a model of “true” population, including “true” haplotype frequencies T. 
2. Do the sampling process, i.e. select or generate individuals according to the population 
model. As a result, we have phase-known sample and sample haplotype frequencies S. 
3. Hide the phase information in the sample, i.e. convert genotypes to phenotypes. 
4. Estimate haplotype frequencies E.  
 
If we compare estimated haplotype frequencies E with “true” population haplotype 
frequencies T, we get the assessment of the validity of the final haplotype frequency.  
If we compare S and T, we get the sampling error. As confirmed in [42], the accuracy of the 
frequency estimation depends on the proper sampling procedure. 
4.7.3 Distance from true frequencies 
To examine how close estimated frequencies E are to “true” frequencies T, we can use the 
similarity index FI  [10]: 
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where ipˆ are the estimated frequencies, ip0 are the true simulated frequencies and h is the number 
of unique haplotypes in the union of both sets (estimated and true). It varies between zero, when the 
sets of “true” and estimated haplotypes with non-zero frequency have empty intersection and one, 
when true and estimated frequencies are identical. This index gives more weight to the high-
frequency haplotypes. 
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holds, so we can express similarity index in other form: 
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Other possibilities of comparison of T, S and E, include Goodness of fit, Pearson’s r and 
Spearman’s coefficient tests. 
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5. Design and implementation of HFE algorithm for stem cell donor 
registry datasets 
This chapter discusses our own design and implementation of the HFE algorithm and its usage 
on datasets of stem cell donor registries – challenges, pitfalls and possible solutions. 
5.1 HLA data from stem cell donor registries 
Databases of stem cell donor registries are unique and very valuable sources for population 
genetic studies. The most of the HLA typing results were obtained in accredited HLA laboratories with 
high quality control standards, which is very important. These data are not “dead”, but they are daily 
used and continuously updated by stem cell donor registries staff in order to find unrelated donors 
for stem cell transplantation. 
On the other hand, HLA haplotype estimation from a sample of a stem cell donor registry is 
demanding because of the following reasons: 
 Missing data. 
 Registry data contain HLA results that have been done by different typing techniques, so it 
contains different typing resolution (see chapter 2.2.3). 
 HLA system is extremely polymorphic and people still find a lot of new alleles, see Table 6 
and Table 7. 
 There are quite a lot of HLA loci for which it would be useful to estimate haplotype 
frequencies: A, B, C, DRB1, DRB3, DRB4, DRB5, DQA1, DQB1, DPA1 and DPB1. Reliable and 
unbiased data of DRB3, DRB4, DRB5, DQA1, DPA1 and DPB1 are rare and insufficient for 
haplotype frequency calculation, therefore for practical reasons, we will consider only A, B, C, 
DRB1 and DQB1. Consequently, haplotypes could have up to 5 loci. 
 
 Number of possible values 
Resolution HLA-A HLA-B HLA-C HLA-DRB1 HLA-DQB1 
Missing data 1 1 1 1 1 
Serology broad 11 32 8 10 4 
Serology split 28 61 10 21 9 
DNA low resolution 21 36 14 13 5 
DNA interm. Resolution 410  510  410  510  410  
DNA high resolution 853 1249 361 659 99 
Table 6: Number of possible values (antigens/alleles) in the HLA system (August 2009) [47] 
 
 Number of possible values 
Resolution HLA-A HLA-B HLA-C HLA-DRB1 HLA-DQB1 
Missing data 1 1 1 1 1 
Serology broad 11 32 8 10 4 
Serology split 28 61 10 21 9 
DNA low resolution 21 36 14 13 5 
DNA interm. Resolution 510  510  510  510  410  
DNA high resolution 2188 2862 1746 1285 193 
Table 7: Number of possible values (antigens/alleles) in the HLA system (January 2013) [47] 
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5.2 Input and output typing resolution 
Our goal is to design and develop a general method that takes as the input a population 
sample data, a stem cell donor registry database, and calculates haplotype frequencies that cover 
user-defined set of loci and each locus is calculated at user-requested resolution.  
When we start to “play” with different typing resolution, we must keep in mind that all 
haplotypes entering the EM calculation and appearing in the result set must be disjoint. 
Example 
configuration 
A/A* B/B* C/C* DR/DRB1* DQ/DQB1* 
#1    Low res.  
#2  High res. High res.   
#3 Serol. broad Serol. broad  Serol. broad  
#4 Low res. Low res.  Low res.  
#5 High res. High res. High res. High res. High res. 
Table 8: Examples of configuration of HLA haplotype frequency estimation 
 
Table 8 shows examples of desired settings. This variability of configuration is quite 
challenging. Let us breakdown all possible combinations of input-output relations at any locus, see 
Table 9.  
 
 Output data - Required resolution of HLA haplotypes 
Input data Serology 
Broad 
Serology 
Split 
DNA low 
res. 
DNA 
interm. res. 
DNA high 
res. 
Missing data {01} {02} {03} {04} {05} 
Serology Broad {11} {12} {13} {14} {15} 
Serology Split {21} {22} {23} {24} {25} 
DNA Low res. {31} {32} {33} {34} {35} 
DNA interm. res. {41} {42} {43} {44} {45} 
DNA high res. {51} {52} {53} {54} {55} 
Table 9: Input and output HLA typing resolutions. 
 
Most of HLA studies work with uniform input level of typing resolution of all individuals. In 
order to have such uniform dataset, they: 
 Exclude volunteers with different typing resolution (e.g. donors without HLA-DR typing) or 
 Collapse serology split level antigens to broad level (e.g. A23 to A9). 
 
We can use datasets with multiple level of typing resolution, because it is not necessary to 
require the level of typing resolution to be statistically independent on the HLA type [48]. 
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In fact, the situation about input data is more complicated, because an individual can have two 
HLA codes of different resolution at one locus and we must have solution that can deal with it. We 
could get results like DRB1*01:XX, 07:01 (mix of low and high resolution). Nevertheless we will 
expect the input HLA typing complains WMDA guidelines for use of HLA nomenclature [15] that is 
true for databases of stem cell donor registries. Therefore we do not have to deal with mix of 
serology and DNA typing results at one locus (e.g. DR1, DRB1*04:XX).  
Table 9 defines 30 different situations that could happen at a locus: 
 Cases {X4} make no sense, neither for practical purposes nor for extreme diversity of 
intermediate resolution HLA codes. 
 (EQ) Cases {XY}, where X = Y, are the easiest ones, because we do not have to convert input 
and output HLA codes.  
 (LO) Cases {XY}, where X < Y, mean conversion of codes from lower to higher resolution. In 
other words, it is expectation of higher resolution typing, given a lower resolution typing. 
Special cases {0Y}, i.e. first row of the table, handle missing data. 
 (HI) Cases {XY}, where X > Y, mean conversion of codes from higher to lower resolution. In 
other words, it is degradation of HLA typing results to lower resolution. 
 
Cases (HI) are also important. The most of studies performing HLA haplotype frequency 
estimation on serology broad/split level just ignore DNA typing results of individuals in the sample. 
But this information should not be ignored, because it can improve the serology typing results of an 
individual. This approach is also in harmony with findings of the study [48]. 
 
5.3 Missing data 
We consider a phenotype to present a missing value when no antigens/alleles are reported at 
a particular locus. We assume that the presence of missing values is independent on hidden values 
and other reported values. 
 
Example: The typing result of an individual could be A1,2 B7,8, so just A and B loci are HLA 
typed. Locus DR is not typed, therefore contain missing values.  
There are several methods how to handle missing values in population data: 
(MI-1)  Ignoring individuals with incomplete information (EH software). This approach introduces 
sampling error and overestimates common haplotypes. 
(MI-2) Treating a missing antigen/allele as any other antigen/allele (ARLEQUIN software). This 
approach generates unreal haplotypes. 
(MI-3) Consider missing value as any allele. The best approach, but computationally demanding. It 
means to generalize definition of jc in equation (1), so now the jc
~   is number of all 
possible genotypes that could lead to phenotype  j. Then sums in equations (13) and (15) 
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iterates through all pseudo-haplotypes, i.e. haplotypes compatible with the given 
phenotype. 
(MI-4) Consider missing value as any allele that is already found associated with the observed 
alleles at the other loci in the dataset where considered to substitute missing values [49]. 
This approach is an optimization of the previous one. The idea behind is based on the fact 
that EM algorithm in the previous approach will gradually withdraw those haplotypes that 
are not directly observed in the sample (in complete phenotypes). This method therefore 
provides the same result as the previous one. 
 The study [49] shows that the MI-4 method is better than MI-1 and MI-2, especially when 
the study is focused on rare haplotypes. 
(MI-5) An enhanced approach of MI-4 (Henk van der Zanden, personal communication, 2008):  
 Transform input dataset with missing values to new one, without missing values  
 Missing values are guessed according to analysis of phenotypes without missing 
values.  
 One phenotype with missing values is substituted by more phenotypes without missing 
values and the original number of individuals of this phenotype is proportionally 
divided between new phenotypes.  
Problem of this approach is there could be missing values which cannot be substituted. 
Advantage of this approach is it simplifies the computation. On the other hand it tries to 
do some work in advance that should be done by the EM algorithm. Its influence on the 
accuracy of haplotype frequency estimation should be tested, but we think it will not 
provide better estimates, maybe the same ones. 
(MI-6)  An enhanced approach of MI-1 [50]: Calculate full (3-locus) haplotype frequencies ignoring 
individuals with incomplete information (like MI-1). Then correct these haplotype 
frequencies by adjusting them according to the ratio of the resulting (2-locus) marginal 
frequencies and the direct estimate from the full registry. 
 
5.4 Lower to higher typing resolution 
HLA typing techniques often give results as ‘ambiguities’, which means the result is not 
perfectly determined (high resolution), but some of the known alleles could be discarded. Such result 
could be a list of possible alleles or multiple allele code. In fact the missing value according to 
approach MI-3 (resp. MI-4) is also a kind of multiple allele code that represents all existing alleles 
(resp. all observed allelic combinations in the sample). The study [49] suggests ambiguities “could 
easily be handled using the same statistics as those presented for missing values”, but “this 
theoretically simple process becomes complicated to implement”. 
 
5.4.1 Mapping serology broad to split values 
These cases refer to the cell {12} in the Table 9. The study [51] is the first one that maps broad 
antigens to all possible split antigens in order to generate all possible genotypes to be considered. It 
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is similar to the approach MI-3 and shows the complexity of HLA system even for serology 
haplotypes.  
 
Example 2 
A9 is mapped to split group {A23, A24}. An individual with phenotype A2, A9; B8, B35 could  
have one of these (split) genotypes:  
 A2 – B8 / A23 – B35 
 A2 – B8 / A24 – B35 
 A2 – B8 / A23 – B35 
 A2 – B35 / A24 – B8 
□ 
 
The worst case for calculation of HLA-A, HLA-B, HLA-DR haplotypes is the phenotype A10,19; 
B15,22; DR5,6 (six broad antigens), resulting in 3456 different possible genotypes. 
 
5.4.2 Overlapping mapping of multiple allele codes 
But the situation with ambiguities is more complex than with missing values. Both MI-3 and 
MI-4 map a missing value to exclusive set of alleles.  
 
 
 
 
Figure 6: Comparison of missing value and other ambiguities. 
 
On the other hand, multiple allele codes are mapped to sets of alleles that have nonempty 
intersection, see Figure 6. Other problem is multiple allele codes can contain only few special alleles 
which are not observable in the registry database as high resolution result. This leads to the 
conclusion that MI-3 and MI-4 do not give the same result for ambiguities, as shown in the following 
experiment. 
 
01:03 01:02 01:01 
01:01  01:02 
01:03  etc. 
Missing 
value 
01:AB 01:AC 
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Experiment 1 
Data set: 
 One individual with A*01:AB (=01:01/01:02) 
 One individual with A*01:AC (=01:01/01:03) 
 One individual with A*01:AG (=01:01/01:06) 
 One individual with A*01:02  
 One individual with A*01:03 
 As we can see A*01:01 and A*01:06 are not directly represented in the dataset, so MI-4 
would not work for A*01:AG. 
Required HLA haplotypes:  
 A* (high resolution) 
Results: After 16 iterations of the EM algorithm with MI-3 strategy, the A*01:01 is the most frequent 
allele (0.447), followed by A*01:02 (0.276) and A*01:03 (0.276) and A*01:06 (<0.001). 
□ 
Experiment 2 
Data set: 
 10 individuals with A*01:AB (=01:01/01:02) 
 1 individual with A*01:AC (=01:01/01:03) 
 1 individual with A*01:02  
 1 individual with A*01:03 
 As we can see A*01:01 is not directly represented in the dataset, so MI-4 would ignore it. 
Required HLA haplotypes:  
 A* (high resolution) 
Results: After 19 iterations of the EM algorithm with MI-3 strategy, the A*01:02 is the most frequent 
allele (0.498), followed by A*01:01 (0.410) and A*01:03 (0.090). 
□ 
As conclusion, for ambiguities we should use similar strategy as MI-3, take into account all 
possible alleles. 
 
5.4.3 Overlapping serology to DNA mapping 
Serology to DNA mapping is very practical, but its impact on EM algorithm hasn’t been 
previously studied. S. GE Marsh publishes mapping of HLA alleles to antigens [52], so in order to get 
HLA serology to alleles mapping, we should calculate the reverse index. Other mappings, such as 
serology to low resolution DNA, can be obtained from the previous one. But it also raises some 
problems. 
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Example 3 (HLA nomenclature as of January 2013 [52]) 
A*02:65 could be A31, therefore A31 should be mapped to A*02:65, A*31:01…A*31:71, 
A*33:09. Reducing this list to low resolution we get A31 mapping to A*02, A*31, A*33. But: 
 EM algorithm would prefer A*02 mapping of A31, because A*02 is more common than A*31 
and A*33. 
 It seems like A31 could be potentially A*02:01, which is not true. 
□ 
Example 4 
Broad A28 has splits A68 and A69. A*02:55 could be A28 or A2 (assumed). Therefore A28 could 
be A*02, A*68 or A*69. In context of A28, the A*02 group contains just one allele (A*02:55), the 
A*68 group contains at least 40 alleles and A*69 contains just one allele (A*69:01). So it is very likely 
the A28 will be A*68. In order to observe how the EM will deal with a phenotype containing A28 in 
the context of real data, we have tried the following experiment. 
□ 
Experiment 3 
Data set:  
 The Cord Blood Bank Czech Republic, November 2008, n = 2825 
 Additional individual with the phenotype PA: A11,28 B*35:XX, DRB1*01:XX. 
Required HLA haplotypes:  
 A*-B*-DRB1* (low resolution - low res. - low res.) 
Results: Table 10 shows distribution of possible genotypes of the phenotype during EM iterations and 
behavior of maximization step (14). 
  
)(
)(~
g
j
g
lk
P
hhP
 
Iteration GENOTYPE 1 
hk: A*02,B*35,DRB1*01 
hl: A*11,B*35,DRB1*01 
GENOTYPE 2 
hk: A*68,B*35,DRB1*01 
hl: A*11,B*35,DRB1*01 
GENOTYPE 3 
hk: A*69,B*35,DRB1*01 
hl: A*11,B*35,DRB1*01 
1 79,642% 19,055% <0,001% 
2 80,609% 19,348% <0,001% 
3 81,737% 18,261% <0,001% 
4 83,170% 16,830% <0,001% 
5 84,432% 15,568% <0,001% 
6 85,379% 14,621% <0,001% 
7 86,044% 13,956% <0,001% 
8 86,496% 13,504% <0,001% 
9 86,806% 13,194% <0,001% 
10 87,023% 12,977% <0,001% 
… … … … 
Table 10: Distribution of possible genotypes of the phenotype during EM iterations in the 
experiment 
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This experiment shows the test phenotype “helps” more genotype 1 than the more accurate 
genotype 2. And the EM tends to prioritize the genotype 1 during its iterations. This behavior will 
lead to the overestimation of the haplotype A*02,B*35,DRB1*01 and underestimation of the 
haplotype A*68,B*35,DRB1*01. 
□ 
This problem comes from two facts: 
 HLA-A antigens are mapped to set of HLA-A* alleles that are overlapping. 
 The maximization step does not reflect relations between HLA alleles of different typing 
resolution. Therefore all feasible genotypes of a phenotype are handled in the same way. 
 
This problem comes from the equations (12) - (14) in combination with MI-3 approach, 
because they do not reflect HLA nomenclature and handle all mapping values in the same way. 
Therefore we propose to change the equation (12) to the extended form: 
(23) 
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Unfortunately we do not know these conditional probabilities. But if we assign  
(24)  
j
lk
c
jphenotypehhgenotypeP
1
   
the EM algorithm will behave in the same way as original approach, because it does not affect the 
equation (14). If the value of  jphenotypehhgenotypeP lk  is higher than 
jc
1
, the genotype lkhh is 
“promoted” over other possible genotypes of phenotype j. If it is lower, the genotype lkhh is 
suppressed. It does not affect convergent properties of the EM algorithm. 
If we know “true” haplotype frequencies, we could easily calculate  jphenotypehhgenotypeP lk . 
This leads to the following algorithm: 
1. Assign  
j
lk
c
jphenotypehhgenotypeP
1
 . 
2. Run EM algorithm, using equation (21). 
3. Calculate new  jphenotypehhgenotypeP lk . 
4. Repeat steps 2 and 3 until  jphenotypehhgenotypeP lk  is “stable” – e.g. until maximal 
relative change of any  jphenotypehhgenotypeP lk  is lower than  . 
  
This approach would be very computationally demanding, since it runs the EM algorithm several 
times.  
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Other possibility is to approximate  jphenotypehhgenotypeP lk  by HLA nomenclature relations.  
 
Example 5 
A31 is mapped to {A*02:65, A*31:01…A*31:71}. The size of the set is 72 alleles (two fields only). 
Therefore the probability the A31 will be A*02:65 is 1/72. Consequently the probability the A31 will 
be A*02 is also 1/72. Genotypes containing A*02 are suppressed among all genotypes of phenotype 
with A31. 
□ 
Experiment 4 
Data set:  
 The Cord Blood Bank Czech Republic, November 2008, n = 2825 
 Additional individual with the phenotype PA: A11,28 B*35:XX, DRB1*01:XX. 
Required HLA haplotypes:  
 A*-B*-DRB1* (low resolution - low res. - low res.) 
Results: Table 11 shows distribution of possible genotypes of the phenotype after run of the EM 
algorithm and behavior of adjusted maximization step using equation (21). 
  
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Iteration GENOTYPE 1 
hk: A*02,B*35,DRB1*01 
hl: A*11,B*35,DRB1*01 
GENOTYPE 2 
hk: A*68,B*35,DRB1*01 
hl: A*11,B*35,DRB1*01 
GENOTYPE 3 
hk: A*69,B*35,DRB1*01 
hl: A*11,B*35,DRB1*01 
38 14,69% 85,31% <0,01% 
Table 11: Distribution of possible genotypes of the phenotype after run of the EM algorithm in 
the experiment 
 
This experiment shows the correction by equation (21) managed to prioritize genotype 2 over 
the genotype 1.  
□ 
 
5.5 Higher to lower typing resolution 
Mapping of higher resolution to lower resolution is quite straightforward. Split serology 
antigen can be easily mapped to broad. Allele codes could be mapped to serology code(s) by [52]. 
Other mapping could be obtained by combination of these two. Therefore we can always get set of 
lower typing resolution codes that are assigned to higher typing resolution code. 
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Example 6 
A*01AB is mapped to A*01 (intermediate to low resolution)  
A*01AB is mapped to A1 (intermediate to split/broad resolution)  
□ 
5.6 Data preprocessing 
For practical implementation of the algorithm, data preprocessing steps are necessary. 
Challenges and problems of the input database are described in the chapter 5.1 
 
5.6.1 Checking of input data 
As the first step, the preprocessor should check input data for errors and bring them to the 
consistent form [51].  
 
5.6.2 Grouping of phenotypes 
Summarization in equation (15) runs over all phenotypes. In highly polymorphic system, it is 
more efficient to sum over individuals, because there are fewer individuals sampled than potential 
phenotypes. It is also very useful to group all the same phenotypes in the sample into one record and 
count number of occurrences jn  of such phenotype. This is especially useful for individual with 
missing data (e.g. HLA-AB typed donors). 
 
5.6.3 Feasible genotypes and haplotypes 
The probabilities appearing in equations (12)-(16) are indexed by both haplotype and genotype 
numbers. Given the observed phenotypes, we can generate and index list of all feasible genotypes 
and haplotypes as proposed in [43]. 
The indexing of haplotypes is natural since a haplotype could be shared by many genotypes 
and phenotypes. However we have found the indexing of genotypes does not substantially increase 
the performance of the EM algorithm on typical HLA samples, because there is almost no 
redundancy.  
Experiment 5 
Data set: The Cord Blood Bank Czech Republic, November 2008, n = 2825 
Required HLA haplotypes: A*-B*-DRB1* (low resolution - low res. - low res.) 
Results:  
 3887 possible haplotypes 
 20198 feasible genotypes 
 20153 unique genotypes 
□ 
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During initialization phase of the EM algorithm all possible genotypes derivable from an input 
phenotype should be generated. This includes finding mapping of all input HLA codes (including 
missing values) to list of output typing resolution codes. Generating such list is time consuming 
procedure (e.g. HLA antigen to list of alleles mapping) and the list occupies a lot of memory space. 
Therefore we have found useful to cache these lists and reuse them. This is especially useful with the 
mapping of missing values to output typing resolution codes. 
 
5.7 Computational problems 
The EM algorithm can theoretically handle an arbitrary number of polymorphic loci and 
arbitrary level of polymorphism. But in practice it is limited by the number of possible genotypes that 
could be handled by computers. 
Number of possible genotypes is influenced by: 
 Number of polymorphic loci – exponential relation, according to equation (1) 
 Sample size 
 Homozygosis – degree of homozygosis of individuals, number of heterozygous individuals 
 Missing data or typing of individuals at different resolution than required 
 Degree of polymorphism at observed loci 
 
Addressing these issues is the main challenge of the EM algorithm implementation.  
 
5.8 Our implementation 
Our object-oriented implementation of the EM algorithm was built by 64bit version of the 
Embarcadero Delphi XE2 compiler. HLACORE library [53], kindly provided by ZKRD, was used as the 
low level library for handling HLA data according to the HLA nomenclature [15]. 
5.8.1 Universal configuration 
We have implemented uniform solution of input-output typing resolution options, see chapter 
5.2. 
The software covers all desired input-output configurations, see Table 12. Since serology 
typing is declining and less accurate, the serology as output resolution is not our point of interest. It 
is better to map serology data to DNA than vice-versa. 
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 Output data - Required resolution of HLA haplotypes 
Input data Serology 
Broad 
Serology Split DNA low res. DNA interm. 
res. 
DNA high res. 
Missing data 
 
Not needed. Done. Done. Does not 
make sense. 
Done. 
Serology 
Broad 
Mapping is 
not needed. 
Done. Done. Does not 
make sense. 
Done. 
Serology Split Not needed. Mapping is 
not needed. 
Done. Does not 
make sense. 
Done. 
DNA Low res. Not needed. Not needed. Mapping is 
not needed. 
Does not 
make sense. 
Done. 
DNA interm. 
res. 
Not needed. Not needed. Done. Does not 
make sense. 
Done. 
DNA high res. Not needed. Not needed. Done. Does not 
make sense. 
Mapping is 
not needed. 
Table 12: Input and output HLA typing resolutions. 
 
5.8.2 Data preprocessing 
The program implements data preprocessing ideas described in this work, including: 
 During initialization phase, conditional probabilities  jphenotypehhgenotypeP lk  are 
calculated, see chapter 5.4.3. This is used mainly for low resolution output. 
 Memory sharing of haplotypes and genotypes, caching of input-output resolution HLA code 
mappings, see chapter 5.6.3 
 
In order to limit the computational complexity, the user can set limit - maximum acceptable 
number of genotypes per donor ( j
c~
), for example 106. This will exclude donors with the poorest 
information about background haplotypes. This approach has to be used carefully as discussed in 
[48] and [54]. 
 
5.8.3 Haplotype data structure and indices 
One of the key issues in the design of HFE algorithm is development of efficient data structure 
that keeps lists of all relevant haplotypes. Fast access to these haplotypes is essential for good 
performance of the HFE algorithm. With the data structure, we perform two critical operations: 
adding new haplotypes (INSERT) and searching for specific haplotype without knowledge of the 
haplotype index (SEARCH). These two operations are frequently called even in the initialization phase 
of the EM algorithm, when the final number of all haplotypes is not known. Then the Expectation 
step of the EM algorithm needs to quickly access specific haplotype with known index (GET) and the 
Maximization step loops though all haplotypes (LOOP) and updates their frequencies. 
In general, a haplotype is a vector of HLA allele/antigen codes, see (26) in chapter 9.2. These 
HLA allele/antigen codes are alpha-numerical strings that can be up to 12 characters long 
(”01:01:01:01N”).  
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Jan Hofmann [55] uses rooted three structures that store antigens/alleles in nodes of the tree. 
First locus is stored in nodes with distance one to the root, second locus in the next level, etc. (see 
Figure 7). 
 
Figure 7: Haplotype data structure as a tree [55] 
 
Data structure of an individual node needs to hold up to thousands of edges to the next level. 
So we still need to address the issue of fast indexing of HLA antigens/alleles in the node and fast 
INSERT operation. The GET operation is now more complicated. So we have rather focused on linear 
data structures. 
Easiest possibility is to index all relevant haplotypes by consequence integers and then store 
them in a list, array or matrix. This is quite easy implementation, requires just O(1) for the INSERT 
and GET operations and LOOP is also easy. But the SEARCH operation requires O(N), which is not 
acceptable. 
We can sort the list of haplotypes by their vector of HLA codes (e.g. alphabetical order). By this 
approach, the SEARCH operation has the complexity O(log(N)), but the INSERT operation has 
increased to O(N log(N)), which might be problematic. We have implemented this approach, but we 
do lazy sorting, e.g. the sorting is not done after every INSERT operation, but after every 100 INSERT 
operations. This decreases 100 times number of calls of the slow sort operation, but increases the 
SEARCH operation by a constant, maximally 100, because these unsorted haplotypes have to be 
checked if SEARCH operation fails on the sorted lists. Constant 100 has been chosen experimentally.  
We have found out the  k constant in the SEARCH operation O(log(N)) = k x log(N) is too high, 
because comparison of two haplotypes requires comparison of several HLA antigen/allele codes, i.e. 
several string operations. Therefore we have encoded haplotype into single integer and reduced the 
haplotype comparison operation by single processor cycle. Encoding is done in this way: 
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 All existing HLA allele and antigen codes at a locus are alphabetically sorted. For example, for 
locus A/A*, we get sequence: “01:01”, “01:02”, etc. 
 We assign them integers, starting from 0. So “01:01” gets 0, “01:02” gets 1, etc. 
 Since there are less than 3000 known alleles at a single locus, all HLA codes at a single locus 
could be encoded by 12 bit integer. 
 Haplotype index is created by concatenation of these HLA code integers. For 5 loci haplotype, 
we get 60 bit integer. Current processors can handle 64 bit integers in single operation. 
5.8.4 Allele list reduction 
Exponential growth of HLA nomenclature allele list in recent years complicates the EM 
algorithm and dramatically increases the computational complexity. However, most of these new 
and rare alleles will never be observed in the sample. Therefore it is good idea to reduce considered 
HLA alleles. This could be done by: 
1. Applying additional knowledge of the sample population or ethnic group and usage of known 
allele list estimated in the past on similar population or ethnic group (e.g. Caucasian). This 
could be for example list of “Common and Well-Documented HLA Alleles” (CWD) [56].  
2. Several runs of the EM algorithm on the sample. We can calculating allele frequencies first, 
then filter less likely ones (e.g. with probability lower than 
n
pi
2
1
 ). 
3. The greedy algorithm that begins with a set of reference alleles defined for particular 
population and adds additional alleles in order by which allele allows the most new donor 
typings to be interpreted. Reinterpretation is done at each cycle and the allele list grows until 
all donors have valid genotype lists. This algorithm has been implemented by NMDP [57]. 
In our implementation, we use the second option, because it is more universal. In case the 
data preprocessing phase finds an HLA code that cannot be interpreted by reduced allele list, it takes 
the first compatible allele outside the filtered range, i.e. it find the most likely allele with the 
probability bellow ip  that interprets the problematic HLA code.  
5.8.5 Partial haplotype list reduction 
Similarly, partial haplotypes (see chapter 9.4) could be pre-estimated and the algorithm can 
reduce haplotype list by filtering those haplotypes that do not match to any of the pre-selected 
partial haplotypes (probability bellow ip ).  
Thanks to strong linkage disequilibrium (see chapter 2.1) we have used this method for B-C 
and DRB1-DQB1 haplotypes. 
5.8.6 Haplotype list reduction 
In extreme case, we can run the EM algorithm with already known list of output haplotypes. 
The EM algorithm ‘just’ estimates their probabilities.  
5.8.7 Genotype list reduction 
If output haplotypes are known before the EM algorithm starts and even their probabilities are 
known (at least approximately), we can filter less likely genotypes (see chapter 5.6.3) with low 
probability. 
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5.8.8 User interface 
 
Figure 8: User interface of our HFE implementation 
 
The algorithm is run via user interface implemented under Windows OS. Figure 8 shows 
screenshot of the window with most important settings: 
 Input: input file with the sample, registry ID selection, file format of the input file (CSV, 
BMDW file format or relational database) 
 Input file filtering: by default, all input phenotypes are accepted, but user can filter out 
phenotypes that do not meet minimum desired level of typing (e.g. low resolution). For 
example, this can be used to filter out donors without DRB1 typing.  
 Loci and output resolution: selection of loci and requested resolution of output haplotypes. 
Resolution can be set individually at each locus (see also chapter 5.2). 
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 EM algorithm options: maximum number of individuals in the sample, finish criteria (see 
chapter 4.5.5), maximum number of iterations 
 Other options: 
o Maximum length of genotype list j
c~
 (see chapter 5.8.2). 
o Serology to DNA weighted mapping (see chapter 5.4.3) 
o Genotype list repository (see chapter 5.8.7) 
o Validation tests and distance calculations between result and reference frequencies 
o Multi-thread initialization: possibility to use parallel computing during the data 
preprocessing phase (see chapter 5.6.3) 
 Optional filters: 
o Allele list reduction (see chapter 5.8.4) 
o Partial haplotype list reduction (see chapter 5.8.5) 
o Haplotype list reduction (see chapter 5.8.6)  
 
5.8.9 Hardware 
We have run experiments on a PC with Windows 7 Professional SP1 64bit, Intel Core i3-2120 
CPU @ 3.30 GHz, 16 GB RAM. 
 
5.9 Other studies and implementations of the HFE algorithms 
5.9.1 Small samples 
Computer programs described in most papers work with quite small instances: 
 [58] (EH): max. 30 alleles per loci 
 [35] (HAPLO): up to 114 haplotypes, 114 observed phenotypes, and 500 genotypes. 
 [42]: 8-14 biallelic markers per gene in 300 individuals 
 [10]: 2-8 highly polymorphic loci with 20 possible alleles. They have considered samples 
where the total number of possible haplotypes did not exceed 16384. 
 [41]: 619 individuals, three loci HLA-A, HLA-B, HLA-C, serological testing 
 
One of the first analyses of stem cell donor registries [59] calculated ABDR haplotype 
frequencies of registries in the 22nd edition of the Bone Marrow Donors Worldwide (1997): 
 HLA-A, HLA-B and HLA-DR 
 broad antigens have been preferentially used instead of their splits  
 some registries were excluded from the analysis because of various problems (e.g. deviation 
from HWE).  
 Maximal size of a registry dataset was about 50,000 individuals. 
 
5.9.2 State-of-the-art HLA studies 
HLA system is much more complex, see Table 6. The biggest state-of-the-art HLA studies are 
performed in Germany and the United States, which have the biggest databases of bone marrow 
donor registries: 
60 
 
 2003 - German Blood Donors [51]: three loci HLA-A, HLA-B and HLA-DRB1; conversion of 
broad to split antigens, 13,000 individuals, about 10,000 haplotypes; a single individual with 
the typing result A10,19; B15,22; DR5,6 (six broad antigens), has 3456 possible genotypes. 
 
 2005 - German registry ZKRD [60] [61]: three loci HLA-A, HLA-B and HLA-DRB1; about 1 
million donors, 412,494 of these individuals were typed for HLA-DRB1 at low or intermediate 
resolution and another 90,673 at high resolution level. HLA-A and B were analyzed using 
serological nomenclature without associated antigens. For high res. frequencies donors only 
typed for A and B were excluded due to algorithmic limitations. Low resolution data were 
then used to correct a possible selection bias in the restricted data set. Computation took 2 
resp. 9 days. 
 
 2006 – ZKRD (presented at the WMDA conference 2006):  HLA-A, HLA-B and HLA-DRB1 high 
resolution haplotype frequencies estimations; 120,000 individuals; 107 haplotypes to 
consider; up to 5 x 108 diplotypes per phenotype to consider; description matrix (specifying 
which pairs of haplotypes are to be considered for a given phenotype) has 1019 elements, 
1010 of them are positive 
 
 2007 – NMDP [62]: three loci HLA-A (max. 21 antigens), HLA-B (max. 42 antigens) and HLA-
DRB1 (max. 250 alleles); 3.5 million individuals; 21 x 42 x 250 = 220,500 total haplotypes; a 
single individual with the typing result A10,19; B15,22 (DRB1 not tested), has more than 9.5 
million possible genotypes. 5.5 hours running on a cluster of five Sun Fire V100 servers (2 GB 
RAM). 
 
 2007 – NMDP [62]: five loci HLA-A, HLA-B, HLA-C, HLA-DRB1 and HLA-DQB1; high resolution; 
comparison of US ethnic groups; up to 6,500 individuals in one ethnic group. Because of 
limitation of the EM algorithm at greater than three loci with registry data, four- and five-
locus haplotype frequencies were estimated using initial EM runs on the two tightly linked 
locus clusters (C-B and DRB1-DQB1) followed by a second three-locus EM run that 
considered the tightly linked clusters as a single locus. 
 
 2008 - ZKRD (Carlheinz Muller, personal communication): five loci HLA-A, HLA-B, HLA-C, HLA-
DRB1 and HLA-DQB1; tens of thousands individuals; high resolution; computed on server 
with 64 GB RAM; program runs more than ten hours. 
 
 2010 – ZKRD [63] [64]: five loci HLA-A, HLA-B, HLA-C, HLA-DRB1 and HLA-DQB1; hundreds of 
thousands of individuals; high resolution. 
 
 2011 – DKMS [65]: 20 thousand Polish stem cell donors, four loci: HLA-A, HLA-B, HLA-C and 
HLA-DRB1. 
 2012 – NMDP (Loren Gragert, presented at the 16th IHIWS conference in Liverpool):  
o five loci HLA-A, HLA-B, HLA-C, HLA-DRB1 and HLA-DQB1 
o NMDP can run EM algorithm on BMDW database, for every registry and every 
country 
o only DNA based typing is considered, but donors without C and DQB1 typing are still 
included 
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o Experience: genotypic ambiguity of BMDW HLA typing is too high for conventional 
EM to be practical. Two main strategies were implemented to reduce ambiguities, 
reducing ambiguity: Allele list reduction by greedy algorithm and Blocks / 
Imputation. 
 
5.10 Comparison of our implementation with others 
For comparison between the main HFE implementations, including our algorithm, see the 
Appendix D. The table shows applications of HLA HFE algorithms of research groups that cooperate in 
the Registry Diversity Subcommittee of the World Marrow Donor Association (WMDA) Information 
Technology Working Group. It gives overview of technology (platforms, programming languages), 
limitations of the algorithms (maximum number of loci, maximum number of phenotypes, accepted 
input), initial and terminating conditions, internal methods (mapping of alleles, handling of 
ambiguities), running time on common tasks and practicalities (output format). 
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6. Reliability of HFE algorithm on registry datasets 
This chapter describes own research results of the reliability of HFE algorithm on real registry 
datasets. The reliability of HFE depends on typing ambiguities of registry donors, computational 
complexity and used heuristics, population size, sample size and population homogeneity. We will 
study these parameters independently in controlled data environment and finally, we will combine 
them together, like in real registry dataset.  
6.1 Typing ambiguities and computational complexity 
Key factors that influence the reliability of HFE are the structure of the registry and ambiguity 
of HLA typing results of donors in the sample. This also influences computational complexity of the 
HFE algorithm, especially values j
c~
. 
Previous studies have also pointed out this important aspect. ZKRD has visualized structure of 
the registry [63] by three-dimensional graph. Every field represents different combination of 
missing/low-resolution/intermediate-resolution/high-resolution typing at five loci (A*, B*, C*, 
DRB1*, DQB1*). The horizontal axe shows the first class loci and the vertical axe shows the second 
class loci. The more dark blue, the relative number of donors is higher. 
 
Figure 9: Visualization of the HLA typing ambiguities in ZKRD [63] 
 
We need different visualization that would better represent computational complexity and 
value j
c~
- number of genotypes per donor. Computational complexity is one of the main obstacles 
when someone tries to calculate HFE. Following example demonstrates the problem. 
Example 7 
 Output: A*-B*-C*-DRB1*-DQB1* high resolution haplotypes 
 HLA nomenclature: April 2012 
 An individual with HLA type A*01:01, B*08:01, C*07:01, DRB1*03:01, DQB1*02:01 is high 
resolution typed, homozygous, so there is just one possible genotype, 1~ jc  
 An individual carrying HLA type A2, B7,62 was typed by serology techniques, so there are 
many possible genotypes, 
26106~ jc . CSCR registry has more than 20 individuals with this 
HLA type. 
□ 
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This example shows j
c~
 can grow to more than 25 digits. In the same way, we have analyzed all 
donors in a registry and visualized number of genotypes per donor   jc~lg  vs. number of donors 
carrying such level of ambiguity    jcD ~lg . E.g. the first donors in the Example 7 has    0~lg jc
and the second has    26~lg jc . 
 
Figure 10: Visualization of the HLA typing ambiguities and computational complexity in CSCR, 
May 2012 
The graph shows huge number of donors with 2510~ jc . Most of these donors are only serologically 
AB typed. 
 
Figure 11: Visualization of the HLA typing ambiguities and computational complexity in ZKRD, 
May 2012 
 
Figure 12: Visualization of the HLA typing ambiguities and computational complexity in DKMS 
Polska, May 2012 [67] 
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Figure 13: Visualization of the HLA typing ambiguities and computational complexity in CSCR, 
May 2012 
The graph shows the most of the donors have 1010~ jc . There are only relatively few donors with 
reasonable number of genotypes. 
 
Figure 14: Visualization of the HLA typing ambiguities and computational complexity in ZKRD, 
May 2012 
The graph shows different the ZKRD registry has much more donors that are better typed than CSCR. 
There are more than 500 000 donors with 510~ jc .  
 
Figure 15: Visualization of the HLA typing ambiguities and computational complexity in DKMS 
Polska, May 2012 
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Figure 16: Visualization of the HLA typing ambiguities and computational complexity in CSCR, 
May 2012 (extract from previous graph) 
The graph shows in detail all donors with reasonable level of HLA ambiguities. Only few hundred 
donors are relevant for HFE algorithm (5 loci, high resolution). 
 
Ambiguity rank of the dataset 
If we calculate the mean of 
 
jc
~lg
, we get interesting ambiguity rank of the whole dataset. 
(25) 
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Following table shows comparison of the datasets. 
Dataset / registry R 
CSCR, May 2012 23.3 
ZKRD, May 2012 15.3 
DKMS Polska, May 2012 7.3 
Table 13: Ambiguity rank of selected registries 
 
6.2 Typing ambiguities 
Previous graphs show extremely big computational complexity of the HFE problem on real 
registry data. Donors with high level of ambiguity (> 1010) do not bring a lot of specific information 
about two underlying haplotypes, because these haplotypes are “hidden” in the set of all compatible 
genotypes (up to 1027). HFE benefit of such donors is very poor, but they bring extreme increase in 
the computational expenses.  
Since 2008, we participate in the Registry Diversity Subcommittee of the Information 
Technology Working Group of the World Marrow Donor Association (WMDA). The group, lead by 
Martin Maiers (USA), Steven GE Marsh (UK) and Carlheinz Muller (Germany) is a great platform for 
discussion, research and development of HFE methods. [56] 
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We have compared different programs for HLA haplotype frequency estimation in a controlled 
data environment. Simulated data set of the same sample size (100 000 individuals) contained the 
same donors, but with different proportions of typing ambiguities.  
The work, summarized below, was presented at the 15th IHIWS conference [66]. Our HFE 
implementation has number 1. 
67 
 
 
 
68 
 
6.3 Population and sample size 
Let’s now focus on sample size and its influence on the reliability of HFE. For this purpose, we have 
done the following experiment (see also chapter 4.7.2): 
 Generate population of N individuals (genotypes). Calculate “Population HF”.  
 Simulate the registry by sampling the population. Take random subsets of 500, 1000, 2000, 
4000, etc. individuals. Calculate “Sample HF”.  
 Convert genotypes to phenotypes (hide phasing information). Estimate HFE, using the 
sample by EM algorithm.  
 Compare distance (22) between HFE of the EM algorithm, “Sample HF” and “Population HF”. 
Results of these experiments are shown in the following graphs. 
 
Figure 17: Sample size and reliability of HFE: Artificial population of 8 000 individuals based on 
[HPE-2010], five loci high resolution typing (A-B-C-DRB1-DQB1).  
 
Figure 18: Sample size and reliability of HFE: Artificial population of 512 000 individuals based 
on [HPE-2010], five loci high resolution typing (A-B-C-DRB1-DQB1).  
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Figure 19: Sample size and reliability of HFE: Artificial population of 10 000 000 individuals 
based on [HPE-2010], five loci high resolution typing (A-B-C-DRB1-DQB1).  
This graph simulates population of 10 million individuals, similar size like the population of the Czech 
Republic and other Central European countries. The experiment gives us very good understanding of 
the sampling error of the small to middle size stem cell donor registry. The sampling error of all 
donors recruited in the Czech Republic (less than 100 thousand donors) is more than 0.1. 
We can also compare HFE of the EM algorithm (on the sample) and the Sample HF.  
 
Figure 20: Comparison of HFE and the sample HF: Artificial population of 8 000 individuals 
based on [HPE-2010], five loci high resolution typing (A-B-C-DRB1-DQB1).  
In general, the sample itself outperforms the EM algorithm, especially with growing sample size. 
When the sample size reaches 100% of the size of the population, there is no sampling error, because 
the sample contains the whole population. But the beginning of the curve might bring unexpected 
(and unreliable) results. With small sample sizes (up to 17% of the population), the EM algorithm 
may outperform the sample itself. This paradox could be observed mainly in small populations. If we 
increase the size of the population, we get the following result. 
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Figure 21: Comparison of HFE and the sample HF: Artificial population of 512 000 individuals 
based on [HPE-2010], five loci high resolution typing (A-B-C-DRB1-DQB1).  
For small sample sizes, the EM algorithm may be still slightly better than the sample itself, but only 
until the sample size reaches about 1% of the population. For the population of the size of the Czech 
Republic, this drops to 0.05% of the population size. 
 
Figure 22: Comparison of HFE and the sample HF: Artificial population of 10 000 000 
individuals based on [HPE-2010], five loci high resolution typing (A-B-C-DRB1-DQB1).  
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true frequency is less than 0.0625, so the algorithm overestimates frequencies of these two 
haplotypes. But there is a quite good chance at least one of remaining 14 haplotypes exists in the 
population. Then EM algorithm finds a haplotype that does not exist in the sample, but exists in the 
population and the overall HFE is better estimates of the sample itself. 
We have discussed this topic with Carlheinz Muller which results in two additional comments: 
 Observations for small sample size depends on ignoring confidence intervals which are 
extremely wide in such cases. Small sample sizes have big sampling error and therefore 
observations related to such samples are not reliable. 
 “The major drawback of EM is that it incorrectly works on a continuous instead of a discrete 
number space. In a sample, all allele or haplotype counts must be integers and the maximum 
should only be sought within such an integer valued domain. … anything depending on 
seriously ignoring this constraint refers to artifacts or useless or unreliable numbers produced 
by this algorithm. This refers in particular to the accuracy of estimates and the low-frequency 
estimates (low = "count in the sample < 3").” 
6.4 Population homogeneity 
All experiments in the previous chapter were done using artificial population based on [HPE-
2010]. But other populations, represented by other HF sets, are more homogenous (see Appendix A).  
To test this influence, we have generated several artificial populations using different datasets 
in the Appendix A. We have found out the HFE depends on the population homogeneity – higher 
homogeneity of the population results in better HFE. The following graph shows the extreme case of 
artificial population based on [FI-2010]. HFEs are 2-10x better than those shown on the Figure 18. 
 
Figure 23: Sample size and reliability of HFE: Artificial population of 512 000 individuals based 
on [FI-2010], five loci high resolution typing (A-B-C-DRB1-DQB1).  
We expect the Czech population is slightly more homogeneous than the German population 
(see Appendix A). This is probably caused by smaller population and country size. It means 
simulations of Czech HFEs could be done using [HFE-2010] and our conclusions are the same or 
slightly worse than the reality (e.g. Figure 19). This means we are on the save side.  
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6.5 Computational complexity 
As discussed earlier, donors with high level of ambiguity (> 1010) do not bring a lot of specific 
information about two underlying haplotypes, but bring extreme computational complexity. Can we 
exclude them? What is the influence on the HFE? 
In order to simulate this dependency, we have selected all German phenotypes [BMDW-
201205] that are at least intermediate resolution typed at loci A*, B*, C*, DRB1* and DQB1*. There 
were 380567 of such records. We have sorted them by growing j
c~
. Then, a subset of N first records 
was selected, HFE was performed and results were compared to [HFE-2010]. 
 
 
Figure 24: Growing sample size, computational complexity vs. reliability of HFE. Used data: the 
ZKRD registry (May 2012), at least intermediate resolution typing (A-B-C-DRB1-DQB1), 5 loci 
high resolution HFE, reference haplotype frequencies [HPE-2010]. 
The Figure 24 shows results of the simulation on ZKRD registry data. First estimate uses just 
about 1 300 donors who are high resolution typed and homogeneous ( 1~ jc ). The third estimate 
uses all high resolution typed donors ( 16~ jc , about 90 000 individuals) and the estimate is very 
good. Mixture of high and intermediate resolution typed donors increase the distance from [HPE-
2010], but with growing sample size, the distance gets closer and closer to [HPE-2010]. However, 
computational costs (time and memory) grow exponentially, so at final stage we managed to include 
451 190 donors with algorithm running time 7,5 hours (PC with Windows 7 Professional SP1 64bit, 
Intel Core i3-2120 CPU @ 3.30 GHz, 16 GB RAM) and the distance to [HPE-2010] was just 0.1. 
6.6 Simulation of real dataset 
We have seen the reliability of HFE algorithm depends on several factors, such as typing 
ambiguities of registry donors, computational complexity (and limitations of hardware), population 
size, sample size and population homogeneity. But real live registry dataset has combination of all 
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these factors. What is the reliability of HFE for a real population? Especially, what is the reliability of 
HFE for the Czech population? 
In order to simulate the reliability of HFE on a registry dataset, we need to have similar data in 
a controlled data environment. 
Therefore, we have designed and run this complex simulation: 
1. Population homogeneity (see chapter 6.4): Take appropriate high resolution HF, with similar 
homogeneity as real population. These are “background haplotype frequencies”. 
2. Population size (see chapter 6.3): Generate the artificial population - create individuals 
according to the population model (HFE). As a result, we have phase-known population and 
its “true haplotype frequencies”. Size of the artificial population will be the same as the real 
population. 
3. Sample size (see chapter 6.3): Simulate the recruitment process - do the sampling of the 
artificial population. Sample size will be the same as the registry dataset. We get “sample 
haplotype frequencies”. Hide the phase information in the sample, i.e. convert genotypes to 
phenotypes. Every real donor has corresponding artificial donor in the simulated dataset 
(donor pair).  
4. Typing ambiguities (see chapters 6.1 and chapter 6.2): For every real donor, analyze the 
typing ambiguity. Simulate the HLA typing of the corresponding artificial donor to the similar 
level of typing ambiguity as the real donor. We get simulated dataset. 
5. Computational complexity (see chapter 6.5):  Estimate haplotype frequencies on the 
simulated dataset (“estimated haplotype frequencies”) using the same techniques, 
algorithms and heuristics as on the real registry dataset. 
6. Reliability of HFE: Count the distance (22) between “estimated haplotype frequencies” and 
“true haplotype frequencies”. This is also approximation of the reliability of HFE of the real 
registry dataset. If “estimated haplotype frequencies” do not contain all loci as “true 
haplotype frequencies” or some of these loci are not estimated at high resolution level, we 
need to convert “true haplotype frequencies” to the same resolution as “estimated 
haplotype frequencies”, before the distance can be counted. 
The first step is difficult, because we need to take some HFs with similar homogeneity as real 
population. But we may not know precisely the homogeneity of the real population. As discussed in 
the chapter 6.4, it is better to take HFs of a population with lower homogeneity than the real 
population. 
But the trickiest is the fourth step that has to be done very carefully. Artificial donor virtual 
HLA typing process must maximally correspond to real donor HLA typing techniques. But the artificial 
donor is different individual (from different population) than the real donor, which complicates this 
step.  
We can do virtual intermediate resolution typing by applying commercial SSOP typing kits and 
their characteristics. This technique has been implemented by NMDP (not published). A problem 
could be selection of the vendor, since we don’t know by what typing technique (serology, SSP, SSO, 
SBT) and what typing kit the real donor was typed.  
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We have implemented different approach that will be demonstrated by the following example. 
6.6.1 Example: Simulation of the CBB Czech Republic 
In this example, we will simulate HFE of the Czech population, using the real dataset of the Cord 
Blood Bank Czech Republic. Simulation steps are: 
1. We take German population and [HPE-2010] as background haplotype frequencies. 
Germany is neighbor country, has the biggest registry in Europe and both populations are 
Caucasian. We expect the homogeneity of the German population is lower than the 
homogeneity of the Czech population, because Germany is about 8x bigger country. This 
is also confirmed by HFE (see the Appendix A). 
2. The Czech population has about 10 million people (May 2012), generate artificial 
population of 10 million individuals. 
3. The CBB has less than 4000 CBUs (May 2012). Simulate recruitment process of 4000 
individuals.  
4. (A) Replace artificial (German) donor by reference donor phenotype in the (German) 
registry. 
i. Select all donors in the reference (German) registry [BMDW-201205] with no 
HLA mismatch [7] (HLA-A, -B, -C, -DRB1, -DQB1) against the artificial donor. 
ii. In the set of these donors, find a donor with the most similar typing 
ambiguity as the real donor (CBU) in the simulated dataset (CBB Czech 
Republic) - take the one with the smallest absolute distance of j
c~
 between 
reference (German) donor and real CBU. This reference donor has our 
simulated HLA typing of the artificial donor. 
5. Estimate HF of the simulated dataset. 
6. Count distance between “estimated haplotype frequencies” of the simulated dataset and 
“true haplotype frequencies” of the artificial population. 
By this approach we get following key properties of the simulated dataset: 
1. Similar population homogeneity, maybe little bit more pessimistic than the reality. 
2. Same population size. 
3. Same sample size. 
4. Similar typing ambiguities ( j
c~
), based on real HLA typing techniques. 
5. Similar computational complexity, see Figure 25. 
6. Similar reliability of HFE, see Figure 26. 
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Figure 25: Simulation of the real registry (Cord Blood Bank of the Czech Republic) by artificial 
population (based on German HFE) and virtual recruitment and virtual donor typing. Used 
data: the ZKRD registry (May 2012), [HPE-2010], CBB Czech Republic (May 2012). 5 loci high 
resolution genotypes (A-B-C-DRB1-DQB1). 
 
The sampling error of 4000 individuals in our artificial 10 million population is 0.275. The HFE 
algorithm is limited mainly by computational complexity, so not all donors could be considered in the 
estimation. The Figure 26 shows dependency between number of donors considered by HFE 
algorithm and reliability of haplotype frequency estimates.  
 
Figure 26: Simulation of reliability of HFE of the Cord Blood Bank of the Czech Republic (May 
2012).  
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The implementation (A) of the step 4 in this example does very realistic virtual HLA typing of 
the artificial donor and it keeps typing relations between loci as it was done by real HLA typing 
techniques – for example using ABDR SSP typing kits.  
However, this approach has also some drawbacks. It may lead to replacement of low 
resolution ABDR typed donor by intermediate resolution AB typed donor with the same j
c~
. We can 
improve the virtual HLA typing by searching only ABDR typed donors, if the donor was ABDR typed 
and other similar improvements, but it would be difficult to cover all possibilities and exceptions.  
Other option would be to “type” loci individually, which is also common practice in the HLA 
laboratories that use typing kits focused only on one locus. We can also do virtual HLA typing at each 
locus independently. This means we need several real donors to simulate HLA typing of one artificial 
donor. 
The alternative implementation (B) of the step 4: 
4. (B) For every locus (HLA-A, -B, -C, -DRB1, -DQB1), simulate the HLA typing process by 
replacing artificial donor typing by reference donor type at the loci.  
i. Select all donors in the reference (German) registry [BMDW-201205] with no 
HLA mismatch [7] at the locus with the artificial donor. 
ii. In the set of these donors, find a donor with the most similar typing 
ambiguity at the locus as the real donor (CBU) in the simulated dataset (CBB 
Czech Republic) - take the one with the smallest absolute distance of j
Lc~  
between reference (German) donor typing at the locus and real CBU typing 
at the locus. This reference donor has our simulated HLA typing of the 
artificial donor at the locus. 
Both approaches (A) and (B) are extremely computationally demanding and such simulation takes 
several days. We have to: 
 Analyze and calculate length of the genotype lists for all donors in both the real and the 
reference dataset. In our case, it means more than 4 million donors for approach (A) and 
more than 20 million loci for approach (B). 
 Run the search for all donors of the simulated dataset in the reference dataset. For the 
registry like in our example (4000 donors only), it means to run 4000 donor searches in the 
file of 4 million donors. For approach (B) it is even 20 000 donor searches in the reference 
dataset. These results must be sorted by decreasing smallest absolute distance of genotype 
list length, which is also not trivial procedure. 
Simulation by approach (B) is more demanding, but gets better results, especially for better typed 
donors (see Figure 25). This is as expected – it might be difficult to find well typed reference donor, 
HLA compatible with the artificial donor. However, if we search by individual loci, it is more likely we 
will find a well typed reference donor, matching with the artificial donor at selected locus. 
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7. Results of HFE on registry datasets 
In this chapter we will present HFE of several populations, mainly in the Central Europe. Given 
a stem cell donor registry dataset, the goal is to estimate the “best possible” haplotype frequencies 
for the registry population. The “best” means: 
 Maximum number of loci, highest possible typing resolution. Gold standard is the estimation 
of 5 loci high resolution haplotype frequencies (A-B-C-DRB1-DQB1). 
 Maximum reliability of estimates, so they represent the whole population.  
These two criteria go against each other – if we estimate higher resolution haplotype 
frequencies with more loci, the reliability will be lower than haplotype frequencies with lower 
resolution or with less loci. 
7.1 Hungary 
 
 
Figure 27: Visualization of the HLA typing ambiguities and computational complexity in the 
Hungarian registry: 5 loci high resolution haplotype frequencies (A-B-C-DRB1-DQB1), May 
2012. 
The Hungarian registry (May 2012) has 6366 active potential stem cell donors in the registry. 
There are almost no donors with small number of typing ambiguities, e.g. only 2 high resolution A-B-
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C-DRB1-DQB1 typed donors (see Figure 27). Even estimation of HLA-A allele frequencies is not 
reliable, because only three high resolution typed HLA-A alleles can be found in the dataset (A*01:01, 
A*02:01 and A*03:01). 
This means we cannot estimate high resolution allele and haplotype frequencies. But we can 
try to estimate low resolution A-B-C-DRB1-DQB1 frequencies.  
 
Figure 28: Visualization of the HLA typing ambiguities and computational complexity in the 
Hungarian registry, 5 loci low resolution haplotype frequencies (A-B-C-DRB1-DQB1), May 
2012. 
This is computationally feasible, but not reliable, since there are only 28 donors typed at all 
five loci by DNA typing techniques. HFE of the simulated dataset have distance 0.452 from the true 
frequencies (estimation of the reliability of 5 loci low resolution haplotype frequencies). 
So finally, we can estimate low resolution ABDR (A-B-DRB1) haplotype frequencies. The 
registry has 3471 ABDR typed donors (54.5%), the rest is AB typed only. 
 
Figure 29: Visualization of the HLA typing ambiguities and computational complexity in the 
Hungarian registry, 3 loci low resolution haplotype frequencies (A-B-DRB1), May 2012. 
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Table bellow shows results of the HFE algorithm, considering all donors, including those AB 
typed only. 
Rank A* B* DRB1* Frequency 
1 01:XX 08:XX 03:XX 0.056816 
2 02:XX 18:XX 11:XX 0.0157 
3 02:XX 44:XX 04:XX 0.014903 
4 02:XX 13:XX 07:XX 0.012188 
5 02:XX 44:XX 16:XX 0.011933 
6 02:XX 27:XX 16:XX 0.011915 
7 02:XX 15:XX 04:XX 0.010172 
8 03:XX 07:XX 15:XX 0.009535 
9 03:XX 35:XX 01:XX 0,008859 
10 02:XX 08:XX 03:XX 0,008491 
Table 14: Most frequent ABDR low resolution haplotype frequencies of the Hungarian registry 
(May 2012). 
 
The simulated datasets has average distance 0.13 from the population, which is also 
estimation of the registry sampling error for ABDR low resolution haplotype frequencies. HFE of the 
simulated datasets have avg. distance 0.324 from true frequencies – this is also rough estimation of 
the reliability of ABDR low resolution haplotype frequencies. 
 
7.2 Slovakia 
There are two registries in the Slovak Republic – one for adult donors (SK) and one public cord 
blood bank (SKCB). The adult donor registry has 3144 donors (May 2012) and the CBB has 1734 units 
(May 2012). Together, we have 4878 individuals and almost all of them are ABDR typed.  
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Figure 30: Visualization of the HLA typing ambiguities and computational complexity in the 
Slovak registries (SK, SKCB), 5 loci high resolution haplotype frequencies (A-B-C-DRB1-
DQB1), May 2012. 
As we can see from the graph, there are about 1200 very well typed donors. This number is 
already comparable with African American, Hispanic and Asian ethnic groups used in the HFE of the 
American study [62]. 
The simulated datasets have average distance 0.27 from the population, which is also 
estimation of the registry sampling error for A-B-C-DRB1-DQB1 high resolution haplotype 
frequencies. HFE of the simulated datasets have average distance 0.444 from true frequencies.  
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Rank A* B* C* DRB1* DQB1* Frequency 
1 01:01 08:01 07:01 03:01 02:01 0,043228 
2 03:01 07:02 07:02 15:01 06:02 0,025822 
3 25:01 18:01 12:03 15:01 06:02 0,012463 
4 02:01 07:02 07:02 15:01 06:02 0,012246 
5 02:01 38:01 12:03 13:01 06:03 0,01157 
6 02:01 44:02 07:04 16:01 05:02 0,010398 
7 02:01 15:01 03:04 04:01 03:02 0,008965 
8 02:01 44:02 05:01 04:01 03:01 0,007578 
9 02:01 13:02 06:02 07:01 02:01 0,006094 
10 02:01 13:02 06:02 07:01 02:02 0,006094 
Table 15: Most frequent ABCDRDQ high resolution haplotype frequencies of the Slovak 
population (May 2012). 
 
Computational complexity of the estimation of low resolution ABCDRDQ haplotype frequencies is 
shown on the Figure 31 and results are provided in the Table 16. 
 
Figure 31: Visualization of the HLA typing ambiguities and computational complexity in the 
Slovak registries (SK, SKCB), 5 loci low resolution haplotype frequencies (A-B-C-DRB1-DQB1), 
May 2012. 
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Rank A* B* C* DRB1* DQB1* Frequency 
1 01:XX 08:XX 07:XX 03:XX 02:XX 0,062804 
2 03:XX 07:XX 07:XX 15:XX 06:XX 0,027063 
3 02:XX 18:XX 07:XX 11:XX 03:XX 0,017698 
4 02:XX 07:XX 07:XX 15:XX 06:XX 0,015893 
5 02:XX 44:XX 05:XX 04:XX 03:XX 0,014746 
6 02:XX 15:XX 03:XX 04:XX 03:XX 0,012922 
7 02:XX 13:XX 06:XX 07:XX 02:XX 0,012229 
8 02:XX 38:XX 12:XX 13:XX 06:XX 0,011592 
9 23:XX 44:XX 04:XX 07:XX 02:XX 0,011306 
10 25:XX 18:XX 12:XX 15:XX 06:XX 0,010862 
Table 16: Most frequent ABCDRDQ low resolution haplotype frequencies of the Slovak 
population (May 2012). 
 
7.3 Czech Republic 
 
 
Figure 32: Visualization of the HLA typing ambiguities and computational complexity in the 
Czech registries (CS, CS2), 5 loci high resolution haplotype frequencies (A-B-C-DRB1-DQB1), 
May 2012. 
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There are two adult registries (Czech Stem Cell Registry and Czech National Marrow Donors 
Registry) and one public cord blood bank in the Czech Republic – together, they have 62 084 
individuals (May 2012). We have already shown example of simulation of the CBB (see Figure 25).  
Rank A* B* C* DRB1* DQB1* Frequency 
1 01:01 08:01 07:01 03:01 02:01 0,074842 
2 03:01 07:02 07:02 15:01 06:02 0,048162 
3 02:01 13:02 06:02 07:01 02:02 0,022213 
4 02:01 07:02 07:02 15:01 06:02 0,019257 
5 01:01 57:01 06:02 07:01 03:03 0,014887 
6 23:01 44:03 04:01 07:01 02:02 0,014544 
7 03:01 35:01 04:01 01:01 05:01 0,01417 
8 25:01 18:01 12:03 15:01 06:02 0,011151 
9 02:01 44:02 05:01 04:01 03:01 0,010263 
10 30:01 13:02 06:02 07:01 02:02 0,009327 
Table 17: Most frequent ABCDRDQ high resolution haplotype frequencies of the Czech 
population (May 2012). 
 
Average distance of high resolution HFEs of the simulated datasets to the true frequencies is 0.355.  
Rank A* B* C* DRB1* DQB1* Frequency 
1 01:XX 08:XX 07:XX 03:XX 02:XX 0,064548 
2 03:XX 07:XX 07:XX 15:XX 06:XX 0,040355 
3 02:XX 13:XX 06:XX 07:XX 02:XX 0,019092 
4 02:XX 44:XX 05:XX 04:XX 03:XX 0,017204 
5 02:XX 07:XX 07:XX 15:XX 06:XX 0,017202 
6 23:XX 44:XX 04:XX 07:XX 02:XX 0,012991 
7 02:XX 18:XX 07:XX 11:XX 03:XX 0,012938 
8 03:XX 35:XX 04:XX 01:XX 05:XX 0,012271 
9 02:XX 15:XX 03:XX 04:XX 03:XX 0,011751 
10 01:XX 57:XX 06:XX 07:XX 03:XX 0,010672 
Table 18: Most frequent ABCDRDQ low resolution haplotype frequencies of the Czech 
population (May 2012). 
 
Average distance of low resolution HFEs of the simulated datasets to the true frequencies is 0.262.  
The following results will be presented without simulated estimation of distance to the true 
frequencies. It is not clear whether simulation can be used for populations that are far from 
reference Caucasian population (north Europe, Cyprus, Africa, etc.). Finish population is much more 
homogeneous than reference German population, but there could be also other hidden problems 
(e.g. linkage disequilibrium). 
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7.4 Finland 
Rank A* B* C* DRB1* DQB1* Frequency 
1 03:01 35:01 04:01 01:01 05:01 0,115949 
2 01:01 08:01 07:01 03:01 02:01 0,066685 
3 03:01 07:02 07:02 15:01 06:02 0,043546 
4 02:01 27:05 02:02 08:01 04:02 0,028982 
5 02:01 07:02 07:02 15:01 06:02 0,028114 
6 02:01 15:01 03:04 04:01 03:02 0,025415 
7 03:01 07:02 07:02 13:01 06:03 0,023425 
8 02:01 15:01 04:01 08:01 04:02 0,021335 
9 02:01 15:01 03:03 13:01 06:03 0,020245 
10 02:01 13:02 06:02 07:01 02:02 0,017724 
Table 19: Most frequent ABCDRDQ high resolution haplotype frequencies of the Finnish 
population (May 2012, 980 donors used, FI and FICB datasets). 
 
Rank A* B* C* DRB1* DQB1* Frequency 
1 03:XX 35:XX 04:XX 01:XX 05:XX 0,096065 
2 01:XX 08:XX 07:XX 03:XX 02:XX 0,051767 
3 03:XX 07:XX 07:XX 15:XX 06:XX 0,036495 
4 02:XX 15:XX 03:XX 04:XX 03:XX 0,027472 
5 02:XX 07:XX 07:XX 15:XX 06:XX 0,026341 
6 03:XX 07:XX 07:XX 13:XX 06:XX 0,02582 
7 02:XX 27:XX 02:XX 08:XX 04:XX 0,023214 
8 02:XX 15:XX 03:XX 13:XX 06:XX 0,021598 
9 02:XX 13:XX 06:XX 07:XX 02:XX 0,020913 
10 02:XX 15:XX 04:XX 08:XX 04:XX 0,016104 
Table 20: Most frequent ABCDRDQ low resolution haplotype frequencies of the Finnish 
population (May 2012, 3356 donors used, FI and FICB datasets). 
 
7.5 Sweden 
Rank A* B* C* DRB1* DQB1* Frequency 
1 01:01 08:01 07:01 03:01 02:01 0,053935 
2 02:01 07:02 07:02 15:01 06:02 0,033879 
3 03:01 35:01 04:01 01:01 05:01 0,026681 
4 02:01 15:01 03:04 04:01 03:02 0,026362 
5 02:01 40:01 03:04 13:02 06:04 0,021377 
6 02:01 44:02 05:01 04:01 03:01 0,018612 
7 03:01 07:02 07:02 15:01 06:02 0,01501 
8 02:01 15:01 03:03 04:01 03:02 0,010864 
9 02:01 40:01 03:04 01:01 05:01 0,009709 
10 02:01 27:05 02:02 01:01 05:01 0,009526 
Table 21: Most frequent ABCDRDQ high resolution haplotype frequencies of the Swedish 
population (May 2012, 812 donors used, S and SCB datasets). 
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Rank A* B* C* DRB1* DQB1* Frequency 
1 01:XX 08:XX 07:XX 03:XX 02:XX 0,045838 
2 02:XX 44:XX 05:XX 04:XX 03:XX 0,04313 
3 02:XX 15:XX 03:XX 04:XX 03:XX 0,030709 
4 02:XX 40:XX 03:XX 13:XX 06:XX 0,022565 
5 02:XX 07:XX 07:XX 15:XX 06:XX 0,017791 
6 03:XX 07:XX 07:XX 15:XX 06:XX 0,017476 
7 03:XX 35:XX 04:XX 01:XX 05:XX 0,017084 
8 29:XX 44:XX 16:XX 07:XX 02:XX 0,011913 
9 02:XX 40:XX 03:XX 04:XX 03:XX 0,009044 
10 02:XX 08:XX 07:XX 03:XX 02:XX 0,008687 
Table 22: Most frequent ABCDRDQ low resolution haplotype frequencies of the Swedish 
population (May 2012, 3296 donors used, S and SCB datasets). 
 
7.6 Cyprus 
The Cyprus Bone Marrow Donor Registry and Cord Blood Bank register more than 120 thousand 
individuals. It is one of the biggest registries in Europe. 
Rank A* B* C* DRB1* DQB1* Frequency 
1 24:XX 35:XX 04:XX 11:XX 03:XX 0,031285 
2 32:XX 35:XX 04:XX 11:XX 03:XX 0,017396 
3 33:XX 14:XX 08:XX 01:XX 05:XX 0,015306 
4 02:XX 35:XX 04:XX 14:XX 05:XX 0,013654 
5 24:XX 18:XX 07:XX 11:XX 03:XX 0,012446 
6 02:XX 44:XX 02:XX 16:XX 05:XX 0,01128 
7 11:XX 35:XX 04:XX 11:XX 03:XX 0,011086 
8 02:XX 51:XX 14:XX 04:XX 03:XX 0,010685 
9 24:XX 35:XX 04:XX 16:XX 05:XX 0,010259 
10 02:XX 35:XX 04:XX 11:XX 03:XX 0,009933 
Table 23: Most frequent ABCDRDQ low resolution haplotype frequencies of the Greek Cypriot 
adult population (October 2012). 
 
Rank A* B* C* DRB1* DQB1* Frequency 
1 33:XX 14:XX 08:XX 01:XX 05:XX 0,02768 
2 24:XX 35:XX 04:XX 11:XX 03:XX 0,024564 
3 32:XX 35:XX 04:XX 11:XX 03:XX 0,015889 
4 03:XX 35:XX 04:XX 11:XX 03:XX 0,010468 
5 11:XX 35:XX 04:XX 11:XX 03:XX 0,010428 
6 24:XX 18:XX 07:XX 11:XX 03:XX 0,010153 
7 24:XX 35:XX 04:XX 16:XX 05:XX 0,010093 
8 32:XX 40:XX 02:XX 16:XX 05:XX 0,009607 
9 01:XX 08:XX 07:XX 03:XX 02:XX 0,009271 
10 02:XX 39:XX 12:XX 16:XX 05:XX 0,009111 
Table 24: Most frequent ABCDRDQ low resolution haplotype frequencies of the Greek Cypriot 
young population (Cord Blood Bank, October 2012). 
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These results have been used by the Cyprus Bone Marrow Donor Registry to study genetic 
changes of the Greek Cypriot population. The study has shown lower homogeneity of the young 
Cyprus populations thanks to mixture with other nations (immigrants, mixed couples). 
7.7 South Africa 
The South African Bone Marrow Donor Registry (SABMR) has more than 64 thousand donors. 
It is the biggest registry in Africa. In fact, there are only two registries in Africa, so the SABMR is very 
unique for the different ethnic groups in the register. We have been asked by medical director of the 
SABMR to focus on the black population.  
 
Rank A* B* C* DRB1* DQB1* Frequency 
1 02:XX 58:XX 06:XX 11:XX 03:XX 0,013385 
2 02:XX 58:XX 06:XX 11:XX 06:XX 0,013385 
3 29:XX 44:XX 07:XX 11:XX 06:XX 0,011765 
4 02:XX 58:XX 03:XX 13:XX 06:XX 0,010348 
5 30:XX 08:XX 07:XX 03:XX 04:XX 0,009766 
6 02:XX 58:XX 07:XX 07:XX 02:XX 0,009374 
7 68:XX 15:XX 03:XX 11:XX 06:XX 0,008583 
8 30:XX 18:XX 07:XX 11:XX 06:XX 0,00853 
9 02:XX 44:XX 16:XX 13:XX 06:XX 0,008019 
10 02:XX 08:XX 07:XX 03:XX 02:XX 0,007241 
Table 25: Most frequent ABCDRDQ low resolution haplotype frequencies of the Black 
population in South Africa, based on 582 individuals (SABMR, October 2012). 
 
Rank A* B* C* DRB1* DQB1* Frequency 
1 33:XX 07:XX 
 
03:XX 
 
0,042531 
2 33:XX 58:XX 
 
13:XX 
 
0,019308 
3 66:XX 58:XX 
 
13:XX 
 
0,018958 
4 02:XX 44:XX 
 
13:XX 
 
0,018881 
5 33:XX 44:XX 
 
11:XX 
 
0,01813 
6 02:XX 58:XX 
 
11:XX 
 
0,017367 
7 24:XX 07:XX 
 
15:XX 
 
0,015563 
8 02:XX 15:XX 
 
03:XX 
 
0,014922 
9 33:XX 15:XX 
 
11:XX 
 
0,0142 
10 02:XX 58:XX 
 
07:XX 
 
0,013871 
Table 26: Most frequent ABDR low resolution haplotype frequencies of the Black population in 
South Africa, based on 2592 individuals (SABMR, October 2012). 
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7.8 Nigeria 
This work [67] proves the need of setting up the new registry in Nigeria, by comparing Nigerian 
HLA haplotype frequencies with Afro-American frequencies. 
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8. Usage of haplotype frequency estimations 
This chapter presents some applications of HFE.  
8.1 Examples of applications 
HLA haplotype frequency estimates could be used to: 
1. To plan development of a stem cell donor registry, especially its size and effectively in finding 
an unrelated stem cell donor for a new random patient [51] [68] [69] [70] [71]. 
2. To select donors that are HLA-A and HLA-B typed only for prospective HLA-DRB1 typing by 
their HLA-AB-phenotype, so that after a defined number of typings performed the expected 
“population coverage” of the registry is maximized [60]. 
3. Selective recruitment of stem cell donors [72]. 
4. To analyze and compare HLA genetic relations and properties of different populations [73] 
[54] [74]. 
5. To calculate the probability of HLA high resolution match between a particular donor and 
patient. Based on this, we can construct new generation of the search algorithm that ranks 
donors according to their probability of HLA high resolution match with the patient. Such 
state-of-the-art approach is used in Germany (Optimatch®) and in the United States 
(HapLogicSM). 
6. To interfere HLA haplotype information for a specific donor, for who we cannot perform 
family study [75]. 
7. To calculate the probability of finding a suitable related or unrelated stem cell donor [76] 
[36]. 
 
This work focuses on the point 5 (and partly also 6 and 7) that is further elaborated in the 
following chapters 9, 0 and 11. However, in the next paragraphs, we will mention some of our results 
related to previous points. 
8.2 Phylogenetic threes and population maps 
We have cooperated with students of the Czech Technical University on their bachelor and 
diploma works. They have used our data as input of their applications. J. Těhník has implemented 
program that can analyse database of a registry and projects trends [77], see Figure 33. 
 
Figure 33: Bachelor work [77] – analysis of database of a stem cell donor registry. 
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L. Kábrt has developed a web application that visualizes HLA data and their location on Google 
maps [73]. For location of the donor, postal codes have been used. For example, the map of Finland 
shows different frequencies of HLA allele groups in regions with Swedish speaking population (see 
Figure 34). In case of the Czech republic, we did not find significant regional differences. Similar study 
has been done in the UK and Germany [70].  
 
Figure 34: Diploma work [73] – analysis of database of a stem cell donor registry. 
 
8.3 HLA Explorer 
We have developed an internet application HLA Explorer (www.hlaexplorer.net) [78] that 
implements user-friendly interface for browsing HLA haplotype frequencies estimations.  Goal of the 
project was to develop system that helps physicians (transplant centers) and coordinators (stem cells 
donor registries) to examine Linkage Disequilibrium of HLA system in order to assist to find suitable 
unrelated stem cells donor. 
The application has more than 200 registered users worldwide.  
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8.4 Phenotype analysis 
Another interesting usage of haplotype frequencies are applications that analyze given 
phenotype and resolve them into possible genotypes. This can be done for multiple populations and 
we get multiple results. If the ethnical or family background of the individual is unknown, the 
comparison  of results may help to associate the patient with an ethnic group and or focus attention 
on rare combinations of patient’s alleles. Such information help to refine the donor search strategy 
before starting the search process.  
The publically available tool with such analysis has been developed by NMDP and is available 
at www.haplostats.org. Another example is the French EasyMatch [30]. 
The phenotype analysis tool is an internal component of the predictive matching (see next 
chapter).  
9. Prediction of HLA Match 
In this chapter we will design new computational method for matching predictions. Top-down 
design of the algorithm is described. We will also compare our approach with other implementations 
in the world (ZKRD, NMDP). 
9.1 Criteria for the new matching prediction algorithm 
A. Usability: We need to compare predictions for all donors. The method must be able to handle all 
cases, patient-donor pairs. 
B. Time: It would be desirable if the method is used in the interactive user interface. We need to 
use the method for at least hundreds of patient-donor pairs. Therefore the method must be able 
to give result quickly, in fraction of one second.  
C. Correctness: If the method gives results, it must be reliable. We need to understand how reliable 
is the method. Therefore the method must be validated. 
9.2 Definitions 
For the purpose of this chapter, we will mathematically define terms haplotype and phenotype 
that have been already defined in chapter 2.1. 
Haplotype ih  is a set of pairs. Each pair is composed of DNA/serology locus designation jl  
and allele/antigen code 
ja according to the HLA nomenclature (see chapter 2.2.2). Empty value is 
considered as special valid code. Let s be number of loci in the haplotype. We can explicitly write 
number of loci as upper index of the haplotype. 
(26) 
)},(),...,,(),,{( 2211 ss
s
ii alalalhh   
jl  must be different from each other. 
Let’s call the corresponding set of loci as haplotype type.  
(27) 
},...,{)()( 21 s
s
ii lllhThT   
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So the condition on distinct 
jl can be written as 
shT si )(  
Where 
X
is the size of the set X (number of elements). 
Phenotype Phen is a set of pairs. Each pair is composed of DNA/serology locus designation 
jl  and a 
set of two allele/multiple-allele/antigen codes 
1,ja  and 2,ja  
})},{,(}),...,,{,(}),,{,{( 2,1,2,21,212,11,11 sss aalaalaalPhen   
We say two phenotypes PhenX and PhenY are the same, if PhenX = PhenY. Otherwise they are 
different. 
We say phenotype Phen matches the haplotype ih  
(and vice versa) if all elements of the haplotype 
ih ”match” with corresponding elements (the same locus) in the phenotype Phen. It means it 
“matches” at least one of two alleles/antigens present at the same locus on the phenotype Phen. Our 
“matching” is described by [5] [7] and basically it means no mismatch is observed. If the locus is not 
present in the phenotype Phen, it is considered as “match”, i.e. no mismatch is observed. 
This predicate (Phen matches ih ) is written as 
 ihPhenM ,  
Example 8 
)}"02:03",1(),"02:04",1(),"03:12",(),"01:38",(),"01:26",{(511 DQBDRBCBAhh   
)}"02:06",1(),"01:15",1(),"02:06",(),"01:57",(),"01:01",{(522 DQBDRBCBAhh   
)}"02:03",1(),"02:04",1(),"02:06",(),"01:38",(),"01:01",{(533 DQBDRBCBAhh   
5})1,1,,,({)( 51  DQBDRBCBAThT . 
The individual A (chapter 2.2.4) could be represented as 
})}"02:06","02:03{",1(}),"01:15","02:04{",1(
}),"03:12","02:06{",(}),"57","38{",(}),":26",":01{",{(
DQBDRB
CBXXXXAPhenA 
 
Locus HLA-A has been low resolution typed, locus HLA-B has been typed by serology technique and 
other loci are high resolution typed. 
Then predicates 
 1,hPhenM A ,  2,hPhenM A  and  3,hPhenM A  
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are all True. 
□ 
9.3 Matching prediction method 
Given an original phenotype Phen of an individual and s-loci haplotype frequencies ih of its 
population, the algorithm selects all s-loci (high-resolution) haplotypes that match with the 
phenotype Phen.  
Then the algorithm loops all matching haplotypes and tries to combine them together into 
pairs forming predicted diplotype ( ih jh ), still matching the original phenotype. ih and jh must be 
complementary, i.e. predicted diplotype form the predicted phenotype kAPhen ,  that also matches 
the phenotype Phen.  
Example 9 
Following the Example 8: Let’s consider these three haplotypes as the only matching haplotypes with 
the phenotype PhenA. They can from three different diplotypes ( 1h 2h ), ( 1h 3h ) and ( 2h 3h ), but only 
)( 211, hhPhenA   matches the phenotype PhenA. 
})}"02:06","02:03{",1(}),"01:15","02:04{",1(
}),"03:12","02:06{",(}),"01:57","01:38{",(}),"01:26","01:01{",{()( 211,
DQBDRB
CBAhhPhenA 
□ 
Let’s focus on probabilities 
jP  
as defined by equations (2) and (3) on page 37. 
Let’s say we have got m possible predicted phenotypes. We normalize their probabilities j
P
 by 
(28) 



m
i
i
j
j
P
P
P
1
*
 
Therefore  
 
1
1
* 

m
j
jP
  
holds. 
*
jP are conditional probabilities expressing the event the given phenotype is in fact predicted 
phenotype j. 
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We use this algorithm twice, to analyze both patient and donor phenotype. Let DjP are 
normalized probabilities of predicted phenotypes DjPhen of the donor, m
D is their count, PjP are 
normalized probabilities of predicted phenotypes PjPhen  of the patient and m
P is their count. 
Finally, we find all predicted phenotypes that are common for the donor and the patient, and 
multiply their conditional probabilities. We get equation for the matching prediction 
(29) 

 

D Pm
j
jk
P
k
m
k
D
j PPmp
1 1

 
Where 0jk , if phenotypes j and k are different and 1jk , if phenotypes j and k are the same, 
i.e. no mismatch (see chapter 9.2). Similarly, the following equation calculates the probability of one 
mismatch 
(30) 
 

D Pm
j
MM
jk
P
k
m
k
D
j
MM PPmp
1
1
1
1   
Where 11 MMjk , if phenotypes j and k have exactly one mismatch (see also [7]) and 0
1 MMjk  
otherwise. 
The probability of a match at specific locus is estimated by  
(31) 
 

D Pm
j
L
jk
P
k
m
k
D
j
L PPmp
1 1
  
Where L is the locus designation and 1Ljk , if phenotypes j and k are the same at locus L and 
0Ljk  otherwise. 
 
9.4 Phenotypes cannot be explained 
Previously described method does not meet criterion A (see chapter 9.1), because it can fail if 
the patient or donor phenotype cannot be “explained”. For patient, it means mP = 0 and the patient’s 
set of predicted phenotypes  PjPhen  is empty. This can happen if: 
 There are no matching s-loci (high-resolution) haplotypes (let’s call them full haplotypes). 
 There are such full haplotypes, but they cannot form matching predicted diplotypes. 
In such case, our method tries to find matching partial haplotypes, i.e. haplotypes with less than s 
loci that match the original phenotype.  
Partial haplotype r
ih is non-empty subset of any original (high-resolution) haplotype 
s
ih . 
s
i
r
i hh  , 
s
i
r
i hh  , 
{}rih  
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)( rihL is partial haplotype type.  
)()( si
r
i hLhL  , 
)()( si
r
i hLhL   , 
{})( rihL  
Matching partial haplotype is the partial haplotype matching the phenotype Phen. Obviously, if the 
(high-resolution) haplotype matches the phenotype Phen, then all derived partial haplotypes are 
matching the phenotype Phen. But it is not always true vice versa, i.e. mismatched (high-resolution) 
haplotype may include matching partial haplotypes.  
Let PHr be the set of partial haplotypes with r loci (0<r<s) 
   
i
t
i
s
i
t
i
t
i
i
t
i
s
i
t
i
t
i
r rhLhhhrhhhhPH  )(  
Conditions 
s
i
r
i hh  and 
{}rih are forced by the condition 0<r<s. 
Matching partial haplotypes MPH are 
  
1
1
1
1
),(





s
r
s
r
r
i
rr
i
r
i
r PhenhMPHhhMPHMPH
 
The method combines these partial haplotypes of different types together, forming artificial 
haplotypes that cover all s loci. In case of two partial haplotypes we get 
 vjtivjtivjtivjtis hhhLhLshLhLsvsthhH  )()()()(002  
The condition shLhL vj
t
i  )()( could be also written as shhL
v
j
t
i  )( , which means the 
artificial haplotype covers all s loci. 
The condition v
j
t
i
v
j
t
i hhhLhL  )()(  means that for all loci that appear in both 
t
ih and 
v
jh , also 
corresponding alleles/antigens must be the same at all sharing loci of both haplotypes. 
But in general, even more than two partial haplotypes can form one artificial haplotype. For triplets 
we get 











w
k
v
j
w
k
v
j
w
k
t
i
w
k
t
i
v
j
t
i
v
j
t
i
w
k
v
j
t
i
w
k
v
j
t
i
s
hhhLhLhhhLhLhhhLhL
shLhLhLswsvsthhh
H
)()()()()()(
)()()(000
3  
… and so on.  
All artificial haplotypes are  

s
i
s
i
s HH
2
  
Full haplotypes could be perceived as 
sH1  
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Haplotype frequency of the partial haplotype is calculated as the sum of all full haplotypes that are 
supersets of the partial haplotype.  
(32) 
 



ij hhj
s
j
t
i pp
;
 
Allele frequencies are special case of partial haplotype frequencies, where 1t . 
Example 10 
Following the Example 8: If the full haplotype type is {A, B, C, DRB1, DQB1}, 5s , then an example 
of partial haplotype type is {A, B, C, DRB1}, which covers 4 loci and the locus DQB1 is omitted. An 
example of partial haplotype is  
)}"02:04",1(),"03:12",(),"01:38",(),"01:26",{(41 DRBCBAh   
□ 
How to find these partial haplotypes? Number of partial haplotype types corresponds to all 
subsets of the full haplotype type, except empty set, which grows by exponential function 12 s . In 
case of five loci, we get 311212 5 s , so there are 31 partial haplotype lists. For each partial 
haplotype type, we need to search for matching partial haplotypes. Then these lists are combined 
together. There are up to  212 s possible pairs of partial haplotype types we need to check. Each 
check combines two lists, so its complexity is  2nO . There are  312 s triplets, etc., so the total 
complexity of the calculation is extreme 
   


s
i
iis nO
2
12  
These are maximum numbers, not all of them make sense to combine, for example {A*} is already 
included in {A*, B*} and the combination does not make sense. I.e. combining such two haplotype 
types we cannot create artificial haplotypes that cover all 5 loci. But still the number of combinations 
is too high for efficient computing.  
Therefore we check only selected partial haplotype types. We have also implemented 
heuristics that first checks bigger partial haplotype types and then, if not successful, others. The 
algorithms uses this order of partial haplotype types: 
 {A, B, C, DRB1, DQB1} … full haplotypes 
 {A, B, DRB1, DQB1} … locus C excluded 
 {A, B, C, DRB1} … locus DQB1 excluded  
 {A, B, DRB1} … typical 3 loci matching (loci C and DQB1 excluded). First versions of 
HapLogic™ and OptiMatch® used these three loci for predictive matching (see chapter 11.3). 
BMDW [6] also uses these three loci for basic matching. 
 {A, B, C} … first class loci 
 {B, DRB1, DQB1} … second class loci and the closest first class locus, see Figure 2. 
 {A} … individual locus 
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 {B} … individual locus 
 {C} … individual locus 
 {DRB1} … individual locus 
 {DQB1} … individual locus 
If the partial haplotype type can be used for explanation of patient (partial) phenotype, we 
select it. We continue to the next partial haplotype type, until we cover all loci by the loci in all 
selected partial haplotype types. Since single locus haplotype types are in the end of the list ({A}, {B}, 
{C}, {DRB1} and {DQB1}), we will always find solution that cover all loci. This means, in the worst case, 
allele frequencies will be used.  
Example 11 
Partial haplotype types {A, B, DRB1}, {B, DRB1, DQB1} and {C} together cover all five loci, i.e. 
haplotype type {A, B, C, DRB1, DQB1}. 
□ 
Note: Theoretically, it could happen even the (phenotype) typing result at a locus cannot  be 
explained by allele frequencies. This means we are trying to estimate probabilities of alleles that have 
never been observed in the underlying population, so allele frequencies are zero or almost zero. This 
can happen if the individual does not belong to the model population.  
After this procedure, we get list of partial haplotype types and corresponding lists of matching partial 
haplotypes. Now, we need to form artificial haplotypes and estimate their frequencies.  
Artificial haplotypes are formed by combination of partial haplotypes from all lists of matching 
partial haplotypes. We take only those combinations that match, i.e. if there is non-empty 
intersection of two partial haplotype types and corresponding partial haplotypes must share the 
same alleles at all loci in the intersection. Haplotype frequency of the artificial haplotype is estimated 
as haplotype frequency of the first partial haplotype (forming the artificial haplotype) multiplied by 
normalized multiplication of all other partial haplotypes forming the artificial haplotype.  
In case of two partial haplotypes t
ih and 
v
jh forming an artificial haplotype 
v
j
t
i
s
a hhh  we define 
artificial haplotype frequency as  
(33) 

v
x
v
jt
i
s
ji
s
a
p
p
ppp ,
 
where: 
 v
xp are frequencies of 
v
xh  (one of them is also 
v
jh ) 
 v
xh  have the same partial haplotype type as 
v
jh  
  vxhPhenM ,  
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This means v
xh  are all possible extensions of 
t
ih , that belong to single partial haplotype type and still 
form matching artificial haplotype with t
ih .  
This definition of partial haplotype frequency is consistent with the property 
j
s
ji
t
i pp , (see 
equation (32)). 
If these partial haplotypes do not share any locus (intersection is empty set), then 1 vxp  
and these are two independent fragments (without common loci) also form new haplotype. 
Haplotype frequency is calculated as multiplication of frequencies of forming partial haplotypes 
(fragments).  
In case three partial haplotypes t
ih , 
v
jh and 
w
kh  forme an artificial haplotype 
w
k
v
j
t
i
s
a hhhh  we 
define artificial haplotype frequency as  


w
y
w
k
v
x
v
jt
i
s
kji
s
a
p
p
p
p
ppp ,,  
where: 
 v
xp are frequencies of 
v
xh  (one of them is also 
v
jh ) 
 
w
yp are frequencies of 
w
yh  (one of them is also 
w
kh ) 
 v
xh  have the same partial haplotype type as 
v
jh  
 
w
yh  have the same partial haplotype type as 
w
yh  
  vxhPhenM ,  
  wyhPhenM ,  
Similarly for four and more partial haplotypes. 
In extreme case, only allele frequencies are used (partial haplotype types {A}, {B}, {C}, {DRB1} and 
{DQB1}) and the haplotype frequency is calculated as multiplication of allele  
Example 12 
Let haplotypes h1, h2, h3 and h4 are the only haplotypes in our haplotype list. 
)}"02:03",1(),"02:04",1(),"03:12",(),"01:38",(),"01:26",{(511 DQBDRBCBAhh   
)}"02:06",1(),"01:15",1(),"02:06",(),"01:57",(),"01:01",{(522 DQBDRBCBAhh   
)}"02:03",1(),"02:04",1(),"02:06",(),"01:38",(),"01:26",{(533 DQBDRBCBAhh   
)}"02:03",1(),"01:15",1(),"02:06",(),"01:38",(),"01:26",{(544 DQBDRBCBAhh   
Let their frequencies be p1 = 0.1, p2 = 0.2, p3 = 0.3 and p4 = 0.4. 
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The frequency of partial haplotype  
)}"02:03",1(),"02:04",1(),"01:38",{(311 DQBDRBBh   
is 4.03111  ppp  
The second partial haplotype of the same type {B, DRB1, DQB1} is 
)}"02:06",1(),"01:15",1(),"01:57",{(312 DQBDRBBh   
with frequency 2.0212  pp  
And the third one is 
)}"02:03",1(),"01:15",1(),"01:38",{(313 DQBDRBBh   
with frequency 4.0413  pp . There is no other partial haplotype type and therefore 
1131211  ppp  
Similarly, partial haplotype 
)}"03:12",(),"01:38",(),"01:26",{(321 CBAh  has frequency 1.0121  pp  
This partial haplotype 
3
21h can be extended by 
3
11h or 
3
13h to form the full haplotype. 
3
21h  and 
3
13h  form new artificial haplotype 
)}"02:03",1(),"01:15",1(),"03:12",(),"01:38",(),"01:26",{(51, DQBDRBCBAha   
with frequency 05.0
4.04.0
4.0
1.0
1311
13
211, 




pp
p
ppa  
The new artificial haplotype 1,ap may help to explain the input haplotype. 
3
21h  and 
3
11h  form again 1h , but with different frequency 
05.0
4.04.0
4.0
1.0
1311
11
212, 




pp
p
ppa  
Summary of the example: All full haplotypes starting with partial haplotype 
3
21h  (only 1h in our 
example) were replaced by all possible extensions of 
3
21h  (two options). This has added new artificial 
haplotype(s). Frequencies of newly formed haplotypes were reshuffled, but total frequency of all of 
them is the same as original haplotypes. 
□ 
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9.5 Validation of the concept of artificial haplotypes 
We form artificial haplotypes are formed only in case normal haplotypes fail to resolve 
(explain) the input phenotype. But it might be useful in more difficult cases. 
In order to validate the concept of artificial haplotypes, we have run the following simulation: 
1. Select all high resolution A*-B*-C*-DRB1*-DQB1* phenotypes from the dataset [BMDW-
2011]. 
2. Try to explain these phenotypes by standard full haplotypes.  
3. Select phenotypes that cannot be explained by full haplotypes, but can be explained by 
artificial haplotypes.  
4. Decrease high resolution to low resolution for all five loci. Estimate probability of low 
resolution phenotype to become the high resolution phenotype, using these three methods: 
 Artificial haplotypes, combined by partial haplotypes that overlap. For example types 
{ A*, B*, C*} and {B*, DRB1*, DQB1*} 
 Artificial haplotypes, combined by partial haplotypes that do not overlap. For 
example types { A*, B*, C*} and { DRB1*, DQB1*} 
 Artificial haplotypes, combined by single locus partial haplotypes (types { A*}, { B*}, { 
C*}, { DRB1*} and { DQB1*}). 
5. Calculate average U value (see (34)) for all these three approaches. 
In the database [BMDW-2011], we have found 595 haplotypes that cannot be explained by 
full haplotypes, but can be explained by artificial haplotypes. We have also used [PROM-CT]. As HFE, 
we have used [ZKRD-2008] and [HPE-2010]. The more haplotypes we have in the HFE, the lower 
number of validation cases for this exercise we find. 
Table 27 displays results of the simulation. It shows the concept of artificial phenotypes has 
better results than other two concepts. 
Dataset Haplotype 
frequencies 
Number 
of 
validation 
cases 
Artificial 
haplotypes, 
combined by 
partial haplotypes 
that overlap 
Artificial 
haplotypes, 
combined by 
partial haplotypes 
that do not 
overlap 
Artificial 
haplotypes, 
combined by 
single locus partial 
haplotypes 
[BMDW-2011] [ZKRD-2008] 595 3.8707379473 4.7190691871 5.9372123576 
[PROM-CT] [ZKRD-2008] 206 0.1497170941 0.3691394013 0.5350892222 
[PROM-CT] [HPE-2010] 68 0.0499954565 0.1668737778 0.2416876335 
Table 27: Validation of the concept of artificial haplotypes, table shows U values 
 
9.6 Situation in the world 
9.6.1 OptiMatch® 
OptiMatch® matching prediction method is roughly described in [63]. The system calculates 
the matching prediction in the same way as our method, i.e. our equation (29) and OptiMatch® 
equation on the Figure 35 are similar. 
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Figure 35: Matching prediction method equation of OptiMatch® [63]  
 
However, other aspects of OptiMatch® matching prediction methods are not published, e.g. 
how to handle patients and donors with phenotypes that cannot be explained (see chapter 9.4). 
You will find more information about the OptiMatch® system in chapter 11.3.1 
9.6.2 HapLogic™ 
As far as we know, HapLogic™ prediction methods have not been published. 
You will find more information about the HapLogic™ system in chapter 11.3.2 
9.6.3 Others 
The Hap-E system [79] uses probably similar prediction method as OptiMatch®. Mathematical 
description, internals and handling of problematic cases has not been published. 
EasyMatch [30] focuses on a priori analyses of patient’s phenotype, rather than patient-donor 
matching predictions.  
10. Validation of Matching Predictions 
This chapter describes methods of validation of the HLA matching prediction algorithm, 
including new simulation framework and provides our results.  
10.1 Methods 
The quality of prognostic matching algorithm and the population model used (allele and 
haplotype frequencies) have to be validated as well. This is usually done by retrospective or 
prospective studies.  
Hans-Peter Eberhard has used the Logarithmic Score Function [63]. 
(34)  
 
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where l is the number of matching predictions and iq are matching predictions. In case of 0iq , the 
value 
410iq  is taken instead. 
More typical option is to use all VTs performed by the registry that meet specific criteria. These 
criteria are: 
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 Patient has been typed at high resolution 
 Donor was not typed at high resolution before the typing request, but has been high 
resolution typed at the time of typing request (or later).  
 No discrepancy between a priori and final HLA type.  
Table 28: Criteria for validation typing request 
 
The review process retrospectively calculates the matching prognosis and compares the 
predicted and observed percentage of allele matches.   
 
10.2 Validation using verification typings 
Validation of matching predictions was carried out similarly to Optimatch/Haplogic. We have 
taken all verification typing requests (VTs, formerly known as confirmatory typing requests, CTs) 
performed by the registry. This was not easy task, because most of the registries recorded such data 
only in paper form. In last four years, we have helped to connect at least 10 stem cell donor registries 
in Europe, Asia and Africa to the EMDIS network (see Appendix C). Thanks to this effort, these 
registries have started to record all international and national VTs in electronic form. This has been 
one of the key building blocks of this work. As VTs we have used EMDIS “Sample request” messages 
(SMP_REQ) [21]. We have collected more than 5000 VTs (Czech Stem Cells Registry, Slovak BMDR, 
Polish ALF Registry, Swedish Tobias Registry, Finnish BMDR, South African BMR and Ezer Mizion 
BMDR). 
From these VTs, we have selected only those that met these requirements: 
 patient has been typed at high resolution level (HLA-A, -B, -C, -DRB1, -DQB1) 
 high resolution (HLA-A, -B, -C, -DRB1, -DQB1) data for loci examined as a VT result (or later) 
 no discrepancy between a priori and final HLA type 
Table 29: Criteria for validation VTs 
 
About one third of VTs satisfy the criteria and that could be used for validation. 
We have faced two problems:  
 unlike ZKRD and NMDP, other registries do not have enough donors that could be used for 
estimation of 5 locus high resolution haplotype frequencies. Haplotype frequencies could be 
calculated, but their confidence is questionable.  
 smaller registries also do not have enough VTs that could be used for validation of the 
prediction algorithm. ZKRD used 9843 CTs in 2008 [8] and 22255 CTs in 2010 [63]. These 
numbers are not achievable by smaller registries.  
In order to overcome these problems, we have approximated the local population to the 
German (ZKRD) population, i.e. we have used our estimation of German haplotype frequencies [D-
1205]. We have also joined VTs from multiple registries using Prometheus software. As result, we 
have collected 1406 VTs for validation. Unlike ZKRD or NMDP that have enough VTs only for their 
donors, our VTs represent a mix of Caucasian donors from different countries. 
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Then we have calculated (retrospectively) the matching prognosis and compared the predicted 
and observed percentage of 10/10 (resp. 9/10) allele matches at 10% or 20% prediction intervals. 
Patient Donor typing before VT Probabilities Donor typing after VT 
(German patient) 
 
A*02:01,03:01 
B*15:01,44:02 
C*03:03,05:01 
DRB1*07:01,11:01 
DQB1*02:02,03:01 
(Finnish donor) 
 
A2,3 
B62,44 
C*03:03,05:01 
DRB1*07:01,11:01 
DQ2,3 
P(10/10)=0.943 
P(9/10)=0.057 
P(A)=0.999 
P(B)=0.943 
P(C)=1.000 
P(DR)=1.000 
P(DQ)=0.999 
(10/10 allele match) 
 
A*02:01,03:01 
B*15:01,44:02 
C*03:03,05:01 
DRB1*07:01,11:01 
DQB1*02:02,03:01 
(German patient) 
 
A*01:01,24:02 
B*08:01,15:17 
C*07:01,07:01 
DRB1*07:01 
DQB1*02:02,02:02 
(Finnish donor) 
 
A*01:XX,24:XX; 
B*08:CCWB,15:XX;  
 
DRB1*07:XX 
P(10/10)=0.049 
P(9/10)=0.017 
P(A)=0.998 
P(B)=0.0668 
P(C)=0.0661 
P(DR)=0.999 
P(DQ)=0.342 
(7/10 allele match) 
 
A*01:01,24:02 
B*08:01,15:01 
C*07:01,04:01 
DRB1*07:01 
DQB1*02:02,03:03 
Table 30: Examples of the VTs. In the first case, the VT has proven, the donor has the same 
typing as the patient (prediction for the 10/10 allele match was 94.3%). In the second case, the 
VT has shown, the donor has multiple mismatches at B*, C* and DQB1*  (low predictions at 
these tree loci). 
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Figure 36: The graph shows the correlation of estimated 10/10 matching probabilities in 10% 
prediction intervals and corresponding observed probabilities. The population model is 
approximated by the German population [D-1205]. Blue bars show 95% confidence intervals of 
estimated probabilities. Since we have less VTs than the ZKRD, confidence intervals are bigger. 
Grey bars show relative number of VTs in each prediction interval. Red dotted line is the ideal 
correlation. The correlation is r = 0.99.  
 
The graph shows the correlation of estimated 9/10 matching probabilities in 10% prediction in-
tervals and corresponding observed probabilities. The population model is approximated by the 
German population [D-1205]. Also in this model, in order to increase the absolute number of cases 
0 
0,1 
0,2 
0,3 
0,4 
0,5 
0,6 
0,7 
0,8 
0,9 
1 
0 
0,1 
0,2 
0,3 
0,4 
0,5 
0,6 
0,7 
0,8 
0,9 
1 
0 0,1 0,2 0,3 0,4 0,5 0,6 0,7 0,8 0,9 1 
O
b
se
rv
e
d
 p
ro
b
ab
ili
ty
 
Estimated probability 
Validation of 10/10 Matching Predictions (n = 1406) 
0 
0,1 
0,2 
0,3 
0,4 
0,5 
0,6 
0,7 
0,8 
0,9 
1 
0 
0,1 
0,2 
0,3 
0,4 
0,5 
0,6 
0,7 
0,8 
0,9 
1 
0 0,1 0,2 0,3 0,4 0,5 0,6 0,7 0,8 0,9 1 
O
b
se
rv
e
d
 p
ro
b
ab
ili
ty
 
Estimated probability 
Validation of 10/10 Matching Predictions (n = 1406) 
106 
 
within the prediction intervals (and shrink the confidence interval), you would need to decrease the 
number of prediction intervals by increasing the size of these intervals. The correlation is r = 0.99. 
Unfortunately, for validation of individual locus predictions, we don’t have enough validation 
cases that would sufficiently fill in all 10% prediction intervals, so we have to do the validation in 20% 
prediction intervals.  
 
Figure 37: The graph shows the correlation of estimated A* matching probabilities in 20% 
prediction intervals and corresponding observed probabilities. The population model is 
approximated by the German population [D-1205]. The correlation is r = 0.98. 
 
 
Figure 38: The graph shows the correlation of estimated B* matching probabilities in 20% 
prediction intervals and corresponding observed probabilities. The population model is 
approximated by the German population [D-1205]. The correlation is r = 0.98. 
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Figure 39: The graph shows the correlation of estimated C* matching probabilities in 20% 
prediction intervals and corresponding observed probabilities. The population model is 
approximated by the German population [D-1205]. The correlation is r = 0.997. 
 
 
Figure 40: The graph shows the correlation of estimated DRB1* matching probabilities in 20% 
prediction intervals and corresponding observed probabilities. The population model is 
approximated by the German population [D-1205]. The correlation is r = 0.99. 
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Figure 41: The graph shows the correlation of estimated A* matching probabilities in 20% 
prediction intervals and corresponding observed probabilities. The population model is 
approximated by the German population [D-1205]. The correlation is r = 0.99. 
 
 
Figure 42: We also used European American (NMDP) population [62] as an approximation of 
local populations. The results were less reliable (r=0.91) than when using the German (ZKRD) 
population, but very similar when decreasing the precision to 20% prediction intervals (r=0.97). 
The graph shows the correlation of estimated 10/10 matching probabilities in 10% prediction 
intervals and corresponding observed probabilities. 
 
Our interpretation of these results and conclusions are: 
 The matching prediction tool works well (the algorithm and its implementation). 
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 The probability matching algorithm can use both German (ZKRD) and European American 
(NMDP-EUR) populations as an approximation for other Caucasian populations. The results 
are satisfactory.  
 The study is limited by small number of local VTs for validation. For this reason, our 
validation uses 10% prediction intervals instead of the 5% intervals used by ZKRD and NMDP. 
Importantly the algorithm can identify donors that are more likely or less likely to be a 10/10 
match.  
If we want to distinguish usage of our predictive matching tool (ProMatch) for the registry in 
general vs. prediction for local donors only, we have to go further. In order to prove it works for local 
donors, we would need to have enough VTs for local donors that we don't have. For example when 
we did analysis in February 2012, there were just 20 useful EMDIS VTs in the Finnish registry 
database. This means we are not able to confirm the ProMatch (with German haplotype frequencies) 
gives reliable estimates for the Finish donors. We can only confirm it works for the mixed Caucasian 
population. 
Intuitively, we expect the ProMatch with German haplotype frequencies will better work for 
populations that are closer to Germans, i.e. there is probably correlation between "genetic distance 
of the population of a small registry to Germans" with "reliability of ProMatch predictions". But 
again, we do not have enough data to prove this hypothesis. 
 
10.3 Validation using simulated dataset 
We do not have enough VTs (patient-donor-sample pairs) that would allow us to decrease the 
prediction intervals. For about 2000 VTs we can use only 10% prediction intervals. If we want to use 
5% prediction intervals (like NMDP or ZKRD), we have to have much more VTs (at least 4000). 
To overcome this problem and extensively validate the algorithm implementation, we can 
create simulated VTs. We have designed and implemented this method to create simulated VTs that 
meet our criteria (see Table 29): 
a) Take the simulated dataset of Czech adult donors (see chapter 7.3). For all of them we know 
both simulated HLA lab typing and background high resolution typing of the artificial donor. 
Almost all AB typed donors have probability lower than 1% and these donors are very rarely 
requested for VT. In order to make it more realistic, we have excluded these donors. Donor 
with probability lower 1% will still form quite big group.  
b) We need some patients records. We can simulate them as well, but this way all patient 
phenotypes would be based on our haplotype frequencies. In real world, some patients 
cannot be “explained” by reference haplotypes. So we will use different approach. Let’s take 
all patients in the CSCR registry that were registered in year 2010 and 2012 (real patient 
cases). We will consider only high resolution typed patients (about 50 thousand patients). 
We get high resolution typed patients from different ethnic groups. 
c) For every donor in the set a), try to find a matching patient in the set b). Match means there 
is no mismatch at HLA-A, -B, -C, -DRB1 and –DQB1, i.e. patient and donor are potential 
match.  
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d) One donor in the set a) can match with multiple patients in the set b) and vice versa. But in 
order to keep maximum diversity of VTs and avoid bias, we will use each patient record and 
each donor record only once. This means, the donor-patient pair is exclusive.  
These triples (simulated donor HLA typing + artificial donor typing + real patient typing) are our 
simulated VTs. This way, we have generated about 8000 VTs that meet our criteria! 
Now we have quite a big database of VTs and we can run several validation procedures, using 
different haplotype frequencies.  
10.3.1 German haplotype frequencies 
The artificial donors were created using ZKRD reference dataset [HPE-2010]. This means these 
artificial donors have similar genetic background as real Germans. Our first key validation is based on 
our haplotype frequencies [HPE-2010]. Since we have enough VTs, we can 5% prediction intervals. 
 
Figure 43: Validation of 10/10 matching predictions using simulated VTs and dataset [HPE-
2010]. UH = 0,3497, R=0.994 
 
Figure 43 shows excellent results. This validates our algorithm design and implementation. All 
other pieces in the validation process are fixed: haplotype frequencies are ideal (true frequencies 
[HPE-2010]) and VTs are very realistic.  
Even if we have excluded AB typed donors, we will still find the majority of estimated 
probabilities bellow 20%. However, all 5% prediction intervals have at least 126 cases. That is 
sufficient amount to calculate the average in all intervals.  
Now, under the presumption the algorithm is validated, we can focus on validation of our 
German haplotype frequency estimates [D-1205]. 
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Figure 44: Validation of 10/10 matching predictions using simulated VTs and dataset [D-1205].  
UH = 0,3500798930, R=0.995 
Again, Figure 44 shows excellent results, almost identical to [HPE-2010]. This validates the dataset 
[D-1205], i.e. the dataset has similar quality as the reference [HPE-2010]. 
10.3.2 NMDP-EUR haplotype frequencies 
 
Figure 45: Validation of 10/10 matching predictions using simulated VTs and dataset [NMDP-
EUR-2007], UH = 0,4126, R=0.987 
Results are slightly worsej than using German population HFE, the system underestimates the 
observed probabilities. Interestingly, also HapLogic III. underestimates the probabilities as well (see 
Figure 50). 
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10.3.3 Frequencies estimated from the simulated dataset 
In this experiment we will estimate haplotype frequencies directly from the simulated Czech 
dataset and then, use them for the validation.  
For HFE, we have used only 2188 best typed donors. This is still comparable to US study [62]. 
The result HFE dataset include only 2253 haplotypes that is much less than [HPE-2010] and [D-1205]. 
 
Figure 46: Validation of 10/10 matching predictions using simulated VTs and HFE from the 
simulated dataset (UH = 0,4735, R = 0,9896). 
 
Results are worse than German population HFE, but still satisfactory. This has important 
consequence for the Czech population HFE: given a real data of the Czech registry database (CS+CS2), 
we can estimate haplotype frequencies of the Czech population (see chapter 7.3). These frequencies 
can be used for the matching prediction algorithm and the algorithm is able to deliver satisfactory 
matching predictions for donors in the Czech registry database. This validation overcomes the 
problem of the lack of VTs that we do not have in the Czech registry database.  
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 Real world Simulation 
True population frequencies Unknown [HPE-2010] 
Registry database Czech registry database CS+CS2 
 
(58 295 donors) 
Simulated Czech registry 
database 
(58 295 donors) 
HFE Algorithm ProMatch HFE (see chapter 5.8) 
Haplotype frequencies Czech population HFE 
(1237 haplotypes with frequency 
>= 10-4) 
Simulated Czech population HFE 
(1340 haplotypes with frequency 
>= 10-4) 
Prediction Algorithm ProMatch (see chapter 9) 
Validation dataset Hundreds of real VTs 
(insufficient number) 
Thousands of simulated VTs 
(sufficient number) 
Validation result Unknown (not enough data) Pass 
Table 31: Validation of the Czech registry (population) matching prediction algorithm using 
simulated dataset and simulated VTs. 
 
These results are promising, especially for registries (populations) that cannot be 
approximated by other population. However, its use for populations with true population 
frequencies that differ a lot from [HPE-2010] is questionable.  
For the Czech population itself, it does not solve the question which HFEs are better for the 
matching prediction of the Czech donors – limited Czech haplotype frequencies [CZ-2012] or 
comprehensive German haplotype frequencies [D-1205]? We are not able to answer this question, 
mainly thanks to insufficient number of real VTs for Czech donors. 
10.4 Situation in the world 
10.4.1 OptiMatch® 
The validation of OptiMatch® (see also chapter 11.3.1) has been done in 2008 with 9843 CTs 
that satisfy these conditions [8]: 
 No high resolution data for the locus / loci examined at the time of request 
 High res data for the locus / loci examined obtained as a CT result (or even later) 
 No discrepancy between the a priory and final HLA type 
For this file of CTs, the ZKRD has calculated (retrospectively) the matching prognosis of 
OptiMatch® and compared the predicted and observed percentage of allele matches in 5% prediction 
intervals. Results are shown on the Figure 47. 
As we have mentioned before, we have adopted the same method in chapter 10.2 
Another published validation of OptiMatch® has been done in 2010 with 22255 CTs. Results 
are shown on the Figure 48. These results are excellent and there is no doubt OptiMatch® is very 
accurate in the HLA predictions of German donors. 
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Figure 47: Validation of 10/10 matching predictions of the OptiMatch® system in 2008 using 
9843 CTs [8] 
 
 
Figure 48: Validation of 10/10 matching predictions of the OptiMatch® system in 2010 using 
22255 CTs [63] 
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10.4.2 Haplogic™ 
Validation methods of Haplogic™ (see also chapter 11.3.2) are probably similar as those used 
by OptiMatch® however details have not been published. Haplogic™ II. results are shown on the 
Figure 49 and Haplogic™ results on the  Figure 50. Haplogic™ takes into account the ethnic group of 
the donor, so it has to use several sets of HFE, which is very interesting feature of the system. But it is 
not clear if NMDP does single validation using CTs from all ethnic groups or if it does validations per 
ethnic group and what are the numbers of CTs. HapLogic™ III currently uses 21 ethnic groups. 
 
Figure 49: Validation of 6/6 matching predictions of the HapLogic II system [graph provided by 
NMDP] 
 
 
Figure 50: Validation of 10/10 matching predictions of the HapLogic™ III system [80] 
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11. Implementation of matching prediction methods  
This chapter presents applications of the algorithms and tools in daily operation of stem cell 
donor registries.  
11.1 ProMatch system 
Our implementation of the matching prediction method is called ProMatch (Probabilistic 
Matching). This functionality has been integrated with the Prometheus system [28] – software for 
stem cell donor registries used in more than 20 countries, mainly in Europe. This was the key step 
towards practical usage of these methods in registry operations.  
11.2 User interface 
Donor search results in Prometheus software are presented in the table. User can switch 
between deterministic matching (“Best First by Match Grade”) and the new probabilistic matching 
(“Best First by Probability”), see Figure 51. This feature is not common in other systems (OptiMatch® 
and HapLogic™). 
 
Figure 51: ProMatch – sorting options of the donor search results: Time, Deterministic 
matching and Probability matching. 
 
Potential donors are listed in the table. The system displays: 
 The probability of 10/10 HLA-A, -B, -C, -DRB1 and –DQB1 allele match, calculated by (29), 
column “P(10/10)”.  
 The probability of 9/10 HLA-A, -B, -C, -DRB1 and –DQB1 allele match, calculated by (30), 
column “P(9/10)”.  
 Probabilities of HLA-A, -B, -C, -DRB1 and –DQB1 allele match at individual loci, calculated by 
(31), columns “P(A)”, “P(B)”, “P(C)”, “P(DRB1)” and “P(DQB1)”.  
Sorting “Best First by Probability” means donors are sorted by “P(10/10)”, then by “P(9/10)”, 
see Figure 52 and Figure 53. 
Display method corrects probabilities by deterministic matching observations: 
 Presented probabilities are rounded and displayed in per cents (0 – 100%). 
 If patient and donor are not mismatched at specific locus (potential match) and displayed 
rounded value would be 0%, it is corrected to 1%. 
 If patient and donor typing do not have the same high resolution allele codes (potential 
match) and the displayed rounded value would be 100%, it is corrected to 99%. 
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Figure 52: ProMatch – example of donor search results (probability matching). The main 
sorting criteria is the probability of 10/10 HLA-A, -B, -C, -DRB1 and –DQB1 match, see column 
P(10/10). 
 
 
Figure 53: ProMatch – example of donor search results (probability matching). The second 
sorting criteria is the probability of 9/10 HLA-A, -B, -C, -DRB1 and –DQB1 match, see column 
P(9/10). 
 
11.3 Situation in the world 
Until 2011, only two HLA matching prediction systems were available in Germany and the 
United States. They have been implemented by two biggest registries in the world – ZKRD and NMDP 
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– that have invested a lot of resources in R&D . Names of these systems are registered and 
protected: OptiMatch® and Haplogic™.  
Except these two systems and our work, some activities are being done by the German donor 
centre DKMS. Their Hap-E system is used only internally [79].  
11.3.1 OptiMatch® 
OptiMatch® [81] [8] is a matching program calculating, for each donor, the probability to be 
allele identical to the patient. The program is developed and used by the German registry ZKRD.  
First version (since October 2006) was based on 3 locus high resolution haplotype frequencies 
had sorting of potential donors according to the probability of 6 of 6 allele match probability (HLA-A, 
-B and -DRB1) and secondary sorting on HLA-C and HLA-DQB1 matching probabilities, age and 
gender. The current version (since June 2008) is based on 5 locus high resolution haplotype 
frequencies (HLA-A,-B,-C,-DRB1 and –DQB1).  
OptiMatch® is able to do serology to DNA mapping, so predictions are calculated also for 
serology typed donors. Current version’s primary matching can be based on the probability of 
matching 6 of 6, 8 of 8 (including C or DQB1) or 10 of 10 (including both) alleles, and then the 
probability of 1 or, finally, 2 allele mismatches. 
User-friendly web based user interface shows a list of potential donors with 7 probabilities: A* 
match, B* match, C* match, DRB1* match, DQB1* match and overall probabilities of 10/10 match 
and 9/10 match. 
11.3.2 Haplogic™ 
HapLogic™ I. [27] was developed and used by NMDP registry since 2006. It works in similar way 
like OptiMatch®. It calculates the likelihood of allele-level matching based on calculated HLA 
haplotype frequencies within major American racial and ethnic populations. HapLogic™ I. predicted 
high-resolution matching at HLA-A, -B and -DRB1 (6 of 6 allele match, 5 of 6 allele match and 2-allele 
match at each of the three loci) [82] [83] [84].  
HapLogic II. (2008) is able to incorporate HLA-C and HLA-DQ matching (2-allele match). The 
latest version III, introduced in November 2011, sorts donors based on probability of matching 10 
alleles, using 5 locus high resolution haplotypes (like OptiMatch®).  HapLogic also uses 5 broad and 
21 detailed race/ethnic groups.  
The web based user interface shows a list of potential donors with several probabilities: A* 
match, B* match, C* match, DRB1* match, DQB1* match and overall probabilities of 10/10 match, 
9/10 match, 8/10 match, 8/8 match, 7/8 match, 6/8 match and for cord blood units also 6/6 match, 
5/6 match and 4/6 match. Screenshot of the user interface is shown on the Figure 54 and example of 
the printed report on the Figure 55. 
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Figure 54: Screenshot of Haplogic™ III [80] 
 
 
Figure 55: Printed report of Haplogic™ III [80] 
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12. Contribution of the work 
Main contributions of this work are: 
 Design and implementation of Haplotype Frequencies Estimation algorithm and further 
exploration and extension of underlying methods 
o We have given an overview of different methods for HFE (chapter 4.3). 
o We have designed and implemented powerful algorithm (based on EM algorithm) 
and tool for HFE that uses real HLA data of stem cell donor registries. Several tricks 
that decreases computational costs, i.e. time and memory were included (chapter 5). 
o We have used j
c~
… a method that transforms qualitative parameters of the HLA 
typing results of an individual to the quantitative attributes (chapter 5.8.2). 
o We have done research of reliability of HFE algorithm on registry datasets. New 
framework that can simulate real stem cell donor registry and estimates reliability of 
HFE (chapter 6) was presented. 
 Probability Matching algorithm and its validation 
o We have designed and implemented the algorithm for the prediction of HLA match 
by top-down design (chapter 9). 
o We have introduced new concept of partial haplotypes (chapter 9.4). 
o We have validated the HLA match prediction algorithm using both real and simulated 
datasets (chapter 10). 
 Real data and deployment of the software into routine operations 
o We have estimated most accurate HLA haplotype frequencies for several 
populations. HFE of some populations have never been published (Hungary, Slovakia, 
Nigeria, etc.). These haplotypes have several applications, not only in the medicine 
(chapter 7). 
o The most importantly, the work has practical benefits for the patients. Results of the 
work (the software) have been deployed in several countries and it is used in daily 
operations of several stem cell donor registries around the world (chapter 11).  
o Main benefits are: it helps search coordinators to identify easy, difficult and (almost) 
futile donor searches, to predict the level of patient-donor matching realistically 
achievable, speed up the donor search by choosing the most promising candidates 
and avoiding detours and make ultra-urgent searches feasible in spite of ambiguous 
or missing HLA data [8]. The speed at which a suitable donor is identified can 
significantly impact patient survival [2]. 
13. Conclusion and future work 
A reliable and efficient search algorithm is the key component of the unrelated stem cell donor 
registry computer system. In our previous work [5] we have implemented combinatorial search 
algorithm that compares patient with donors by counting all known and visible HLA mismatches. In 
this work we have designed and implemented a new probabilistic matching method. The production 
software system combines both methods together, the first one for rough pre-selection and the 
second one for fine grading and sorting. 
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In the first part of the work, we have given the overview of search algorithms, their design and 
implementation aspects (chapter 33.1). A top-down design approach that first lists algorithm 
requirements, specifies input and output parameters and then goes deeper into details, was 
selected. The importance of validation prior to the deployment of a new matching algorithm has 
been emphasized (chapter 3.5).  
In the introduction, we have posed these questions that represent underlying goals (chapter 
1.1): 
How can we design and implement algorithm that creates population model?  
Haplotype frequencies are the basis for modern methods for unrelated donor searching. 
However, the problem of estimation of HLA gene and haplotype frequencies of a human population 
is very difficult (chapter 5.1). We have mathematically formulated the problem (chapter 4.2). Then 
we provided an overview of all methods that could be used for its solution (chapter 4.3). Different 
methods were discussed, especially its possible usage for databases of stem cell donor registries 
(chapter 4.4). Bayesian methods are also promising and worth further investigation (chapter 4.3.5). 
But currently we think the maximum likelihood approach with the Expectation-Maximization 
algorithm is the best approach in our situation (chapter 4.5). Properties of the algorithm (chapter 
4.6) and reliability of results were discussed (chapter 4.7). We have shown the complexity of HLA 
system and databases of stem cell donor registries and reasons for its computational difficulties 
(chapter 5.1). 
We have proposed a framework of arbitrary HLA typing resolution as user-specified input and 
output of the EM algorithm (chapter 5.2). It is generalization of all previous efforts of dealing with 
data of multiple typing resolutions. Several methods of handling missing values were discussed and 
compared (chapter 5.3). We have presented some examples and results of experiments that show 
these methods cannot be easily applied for serology to DNA mapping. We have proposed a 
modification of the EM algorithm that solves the problem (chapter 5.4). 
The EM algorithm in our context is very computationally demanding (chapter 5.7). In our 
implementation (chapter 5.8), we have used several optimizations that speed up the process and 
save computer memory. 
We have presented the situation in the world and overview of the state-of-the-art HLA 
haplotype frequencies estimation programs (chapter 5.9). Our implementation was compared with 
these programs in the international workshop project that tested behavior of EM algorithm in 
controlled data environment and within the scope of this exercise it provided similar results as 
algorithms of other international research groups (chapter 5.10). 
What are the properties and reliability of the model (HFE) in general?  
We have approximated local populations by its stem cell donor registry datasets of different 
sizes and structures. In order to better understand the quality of the result model, we have studied 
different properties of the EM algorithm in the controlled data environment. We have inspected 
quality dependencies on typing ambiquities (chapter 6.1 and chapter 6.2), population size (chapter 
6.3), sample size (chapter 6.3), population homogeneity (chapter 6.4) and restriction of 
computational complexity (chapter 6.5). The final simulation of real stem cell donor registry dataset 
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has combined all these aspects together and provided approximation of the distance of HFE and true 
population frequencies (chapter 6.6). 
We have applied our methods and estimated HLA-A*-B*-C*-DRB1*-DQB1* haplotype 
frequencies for Czech, Slovak, Hungarian, Finnish, Swedish, Cypriote, South African and Nigerian 
populations on the best possible resolution (chapter 7). Such precise estimates of these populations 
have never been published. Our results have been already used in different analyses of stem cell 
donor registries in these countries.  
But possible usage of the data exceeds the field of stem cell transplantation. We have 
presented some examples of other applications (chapter 8).  
How can we design and implement the probabilistic matching algorithm?  
We have defined criteria for the matching prediction algorithm (chapter 9.1) and then 
designed the new computational method (chapter 9.2 and chapter 9.3). A lot of intention has been 
dedicated to special cases, where standard method fails and patient or donor phenotypes cannot be 
resolved (chapter 9.4). We have proposed a system of so called artificial haplotypes and their usage 
in matching predictions. This proposal has been validated on real data (chapter 9.5). 
How can we validate the whole system? Can we apply it for all registries and populations?  
The search algorithm cannot be deployed, if it is not validated. The crucial element of 
validation is the availability of sufficient amount of data (validation cases). Five years ago, most of 
registries in our interest had all these data only in paper form. Since then, we have implemented and 
deployed automated software systems (implementation of EMDIS) in more than 15 countries that 
support daily operations of these registries. One of the outputs of these efforts was the database of 
validation cases in electronic format that was used in this work for validation of the matching 
prediction algorithm and HFE. We have collected more than 1400 validation cases, but still it was not 
enough for detail validation (chapter 10.2). 
We have done also another validation, using simulated datasets (chapter 10.3). By this method 
we have validated both our probabilistic algorithm and HFE [D-1205], the approximation of European 
Caucasian population model. 
 
This work was not only academic research. Designed algorithms and methods have been 
implemented (chapter 11) and deployed in several countries in Europe and help search coordinators 
of stem cell donor registries in daily work to find the best match for patients in need. First registry 
that adopted these algorithms was the Czech Stem Cell Registry in Prague. Nowadays, match lists for 
all Czech patients are ranked and can be sorted by matching probabilities. This helps to identify 
difficult searches, predict realistically achievable results and speed up the donor search.  
Deployment of the system in several other countries is on the way, for example in Finland, 
Sweden, Switzerland, Slovakia, Belgium, England, Ireland, etc. We are in touch with all of them. 
There are also some countries that are interested as well, but we don’t have reliable solution 
yet. These are populations that do not belong to European Caucasian group, such as South Africa, 
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Argentina, Saudi Arabia, etc., but also some minorities in Europe, such as gypsies. The problem is we 
cannot approximate them by Caucasians and we don’t have enough data for estimation of their own 
high resolution haplotype frequencies. We also don’t have enough validation data to verify any kind 
of proposed solution. Overcoming of these problems will be our future work. 
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Appendix A: Used datasets 
 
ID Description Number of 
haplotypes 
Haplotype Rank 
of the median 
haplotype 
[FI-2011] HLA Haplotype Frequencies of the Finnish 
registry, calculated in 2011 by David Steiner 
>= 10-4: 442 
>= 10-5: 3093  
20 
[CZ-2011] HLA Haplotype Frequencies of the Czech 
population, calculated in 2011 by David 
Steiner 
>= 10-4: 1236 
>= 10-5: 3746 
93 
[CZ-2012] HLA Haplotype Frequencies of the Czech 
population, calculated in 2012 by David 
Steiner 
>= 10-4: 1476 
 
96 
[NMDP-EUR-
2007] 
HLA Haplotype Frequencies of the NMDP 
registry [62], Caucasian population, 
calculated in 2007 
3380 102 
[ZKRD-2008] HLA Haplotype Frequencies of the ZKRD 
registry, calculated in 2008 
7686 154 
[HPE-2010] HLA Haplotype Frequencies of the ZKRD 
registry [63], calculated in 2010 
24449 158 
[D-1205] HLA Haplotype Frequencies of the ZKRD 
registry (May 2012), calculated by David 
Steiner 
33102 216 
Table 32: HFE datasets and their identification used in the experiments of the work 
 
 
Figure 56: HFE datasets used in the experiments of the work, frequencies of top 20 haplotypes 
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Figure 57: HFE datasets used in the experiments of the work, cumulative frequency of top 20 
haplotypes 
  
Figure 57 demonstrates heterogeneity of datasets. This corresponds with the statistics 
“Haplotype Rank of the median haplotype” (see Table 32). Due to small registry size and sampling 
error, we expect Czech population is more heterogeneous than we can currently see.  
Other referred datasets 
[BMDW-2011] … BMDW Database [6], February 2011 
[BMDW-201205] … BMDW Database [6], March 2012 
[PROM-CT] … EMDIS Verification Typing requests and their results from selected registries running 
Prometheus software (see Chapter 10.2) 
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Appendix B: Stem cell donor registry software specification 
Text has been taken from [85]. 
WMDA standards require that ‘all patient and donor communications and records must be 
stored to ensure confidentiality and to allow for traceability of the donors and steps of the donation 
process’ (WMDA 5.01.2).  
This section describes architecture, data and functional requirements of the registry IT system. 
It is essential that the registry analyses the following: 
● what are the key modules and functions of the system 
● what information and how it should be stored on the database 
● what are the business processes of the registry and how should they be supported by the 
system 
● who are the end users of the system, what are their roles in the system 
● what are the interactions of the system with the outside world, what interfaces should be 
built 
 
The architecture of the system follows the stem cell donor registry organisation. There are several 
aspects: 
● Situation: The registry might be completely independent, located in the administrative 
building or be to part of a hospital, blood transfusion institute or other medical organisation. 
If the registry belongs to the bigger medical organisation, it has to follow specified rules and 
usually has to be well integrated. Very often, small registries are organisationally connected 
with the HLA laboratory, which necessitates the interface between systems of these 
departments. 
● Donor centres: The registry may be the national HUB that does not recruit donors directly, 
but cooperates with the network donor centres and cord blood banks. In some countries, the 
registry does not have access to donor contact details, so the donors may not be contacted 
directly. In this case this ‘master record’ of the donor is in the donor centre and the registry 
only has a copy. Other settings, typical for small registries, are based on integrated registry 
with the donor centre. Donor recruitment is organised by the registry itself or a network of 
partner organisations that, after recruitment, transfers all donor data to the registry 
database, so the master record of the donor is managed by the registry itself. 
● Access to the registry database is usually restricted registry staff. Partner institutions must 
contact the registry in order to access the database or changes will be visible after next off-
line upload of partner institution data (e.g. cord blood bank). The alternative option is to 
build an on-line interface or allow partner institutions to access the database directly, for 
example, donor centres and cord blood banks can manage their donor, CBU records and 
transactions directly. The registry may look like a single institution for the international 
community (EMDIS, international registries), but is actually a network of donor, transplant 
and search coordination centres that are spread across the whole country. 
 
The list of key functional requirements that a registry may consider to include, when considering new 
or improving existing registry system: 
● Donor database is the key module. Donor record must include: 
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○ Donor identification: a unique, invariant registry ID is the primary reference, but a 
data set can also include social security number, donor centre ID, recruitment ID, 
cord blood bank ID, ID of the mother of the CBU, ISBT128 donation code, stored 
sample ID, stored DNA ID, EMDIS ID, among other fields. 
○ HLA data: separate fields for serology and DNA typing results [15], typing laboratory, 
date of typing, primary typing data, NIMA, etc. The registry should consider of how 
HLA data are imported into the database as this may be from either an internal or an 
external source. Reference to the white paper [15] has to be made regarding 
standardisation of nomenclature and data formatting.  
○ Demographics: name, title, gender, date of birth, ethnic group, insurance company, 
etc. 
○ Relationships: family or personal relations to other donors or patients, used for 
family reports of the patient 
○ Recruitment: donor centre, date of recruitment, recruitment method (website, 
patient-draft, blood donor, etc.), blood donor flag, platelets donor flag, etc. 
○ Donor status: reservation of the donor, temporary or permanent withdrawal, reason 
of withdrawal (age, medical, personal, etc.) 
○ Contact details: permanent, temporarily and work address, email, phones, social 
media networks, communication language, preferred contact, history of 
communication with the donor, etc. 
○ Medical questionnaire: weight, height, blood group, kell, haemoglobin, number of 
pregnancies, number of blood transfusions, donor consent to different types of 
donations, diseases in the past, etc. 
○ Infectious disease markers: CMV status, Toxoplasmosis, EBV status, HIV status, HIV 
p24 antigen, antibodies to HIV, hepatitis B and C status and antibodies, Lues status, 
ALT status, etc. with dates of tests and laboratories that performed tests. 
○ Products: information about the stored donor samples or cord blood unit product, its 
position in the freezer, etc. 
○ Cord blood unit data: volume of CBU, nucleated cells, CD34+ cells, mononucleated 
cells, white blood cells, processing methods, fractions, mother tests, etc. 
○ Harvests: date and place of harvest, date and place of transplant, patient ID, source 
of stem cells (bone marrow, PBSC, DLI, cord blood, other) 
○ Audit: who and when has inserted or modified the donor record, search-able history 
of changes of the donor record (who, when, old data, new data). 
● Patient database functions include: 
○ Need of the record for both national and international patients 
○ Patient identification: unique, invariant registry ID, but can also include social 
security number, transplant centre ID, hospital record ID, EMDIS ID, physician, etc. 
○ HLA data: separate fields for serology and DNA typing results [15], typing laboratory, 
date of typing, primary typing data, etc.  
○ Demographics: name, title, gender, date of birth, ethnic group, insurance company, 
etc. 
○ Relationships: family or personal relations to donors, used for family reports of the 
patient 
○ Patient status: donor search status, transplant status, closure of the case (date, 
reason) 
○ Medical information: diagnosis, disease phase, weight, blood group, CMV status, etc. 
○ Transplants: date and place of harvest, date and place of transplant, donor ID, 
source of stem cells (bone marrow, PBSC, DLI, cord blood, other), etc. 
○ Audit: who and when has inserted or modified the patient record, search-able 
history of changes of the patient record (who, when, old data, new data). 
● Both donor and patient database must be searchable by different attributes. 
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● Quality control: the system should control quality of data according to registry policies. 
There should be no expired reservations of donors, no over aged donors that are ‘available 
for transplant purposes’ on the searches, no donors missing critical data (e.g. date of birth, 
gender), HLA data should be always valid according to the latest HLA nomenclature (renamed 
or deleted alleles should be corrected), etc. 
● Regular update of reference tables of HLA nomenclature [16] and multiple-allele-codes [22].  
● Reports: customizable reports of donor and patient details, export to PDF files, letters and 
emails to donors by user-defined templates. 
● WMDA annual report: Many registries do not systematically collect data for the WMDA 
annual report; leading to time spent searching paper records/excel spreadsheets when 
preparing the WMDA questionnaire. There is a huge advantage to building in the 
functionality to generate this data automatically at the start of the project. This also 
increases the reliability of data reported to WMDA.  
● Donor searches: The donor search algorithm is the key and probably most difficult element 
of the stem cell donor registry software. It should follow WMDA recommendations and 
guidelines. For more information about the search algorithm see the section ‘Search 
Algorithm’. 
● Management of requests: the system must allow users to create and track different national 
and international requests for donors. This includes typing requests, VT sample requests, 
IDM requests, donor reservation requests and workup requests. Traceability of requests 
means clear information about the status of the request (result, inability to do the service, 
cancellation, denial) and related events (acknowledgement by the partner, contact of the 
donor, reminders, invoice).  
● The system should support the work-flow management of requests for different scenarios 
(e.g. unsuccessful CT collection, cancelled workup). Each step in the search process (e.g. 
patient registration and any request, result or update) shall be documented with all relevant 
attributes and a time stamp (WMDA 5.04.3). Management of requests includes both: 
○ National requests - national patient and national donor 
○ International requests - national patient and international donor or vice versa; 
electronic on-line requests (EMDIS or web interface) and fax requests (outside 
EMDIS) 
● Financial module can be integrated into the request management work-flow. Closed 
requests are usually invoiced to the requesting institution. Integration with external 
economical software system requires synchronisation of services (invoice items) and clients 
(invoice recipients). 
● Transplant records, donor and patient follow-up records with automated reminders of 
incomplete or missing records.  
● Document management system: possibility to store and maintain different kinds of 
electronic documents, linked to donor, patient, search and other types of records. 
● International interfaces: the registry should be well integrated to the international 
community, mainly due to efficient donor searches: 
○ BMDW: regular export of donor and CBU database to Bone Marrow Donors 
Worldwide (www.bmdw.org) 
○ EMDIS, EMDIScord: on-line peer-to-peer network of stem cell donor registries 
(www.emdis.net). You will find more information about the EMDIS system bellow in 
this chapter. 
○ NMDP: some international registries are listed as donor centres in the NMDP 
network, so they regularly export data to NMDP database (www.nmdp.org). 
○ Netcord: member cord blood banks of this organisation regularly export data to the 
central database (www.netcord.org/). 
○ HLA: regular import of the current HLA nomenclature 
(http://hla.alleles.org/wmda/index.html, NMDP allele code nomenclature) 
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● National interfaces: the registry serves as the national HUB that connects different 
institutions and individuals within the country. Following on-line interfaces might be useful: 
○ HLA laboratory: registry sends electronic typing requests for its donors and patients 
to the laboratory and HLA typing results are returned to the registry. The registry can 
also access information about donor samples stored in the HLA laboratory freezers, 
so registry coordinators know if they can use this stored DNA sample for the 
additional HLA typing.  
○ Donor centres: donor centres and cord blood banks in the registry network may have 
their own IT systems that should be interfaced to the registry system. 
○ Harvesting centre: once the patient-donor pair is identified, the registry may send 
donor record to the harvesting centre system and get back details about the stem 
cell product. 
○ Search units: search units in the registry network may have their own IT systems that 
should be interfaced to the registry system. 
○ Transplant centres: transplant centres and hospitals need to communicate with the 
registry. An on-line solution instead of fax / paper / phone solution is desirable. 
○ Donors: On-line web portal helps to keep the contact with donors. Such portal can 
include contact details change form, on-line forum, news from the registry, 
reimbursement form, etc. Some registries also use social media networks such as 
Facebook or Twitter. 
○ Sponsors: On-line web portal for registry sponsors may increase their motivation. 
The system can manage sponsor accounts and show statistics how many donors 
were recruited for the sponsorship, how many of them were requested for VTs, 
workups, etc. 
 
TIP: It may seem that a registry system stores and manages the HLA typing results in the same format 
as the HLA laboratory information management system (LIMS), and some registries have 
implemented such data storage.  
It is a mistake to use these in search algorithms. The main differences between registry database and 
HLA LIMS database are: 
● The registry system needs fast access to the most current and comprehensive HLA typing 
results, which does not always mean the last test typing. This may be combination of 
multiple tests performed in the past by multiple typing techniques. The registry system 
always needs access to the full set of all loci that should be stored at one place, while the 
HLA lab system order includes only requested tests and loci, so HLA typing results of an 
individual may be spread in multiple typing orders. 
● When the HLA lab supervisor approves the order results, it cannot be changed in the lab 
system. However, the registry system has to keep historical HLA typing results up-to-date 
according to the latest HLA nomenclature, so it needs to update them (deleted and renamed 
alleles, new HLA nomenclature). 
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Appendix C: Inter-Registry Communication System (EMDIS) 
Text has been taken and adapted from [85]. 
Reliable communications and data transfer of donor and patient records between all partners 
in this huge network is one of the most important success factors in stem cell transplantation. 
The internet gives us great opportunities in registry to registry connections, including the 
software support of the whole process - from the preliminary search request to transplantation. 
EMDIS (European Marrow Donor Information System) [31] [86] [87] [88] is an open computer 
network for data exchange among different unrelated hematopoietic stem cell donor registries. 
Today, it covers around 75% of all potential unrelated stem cell donors and cord blood units 
registered in BMDW (www.bmdw.org) and became the de-facto standard communication system for 
unrelated HSCT registries worldwide. The EMDIS community provides documentation, status 
information, software tools, support and a project management platform [31] (www.emdis.net).  
C.1 Technical background 
The decrypted content of an EMDIS message is a text in special format, called the Flexible 
Message Language (FML). EMDIS emails are not read by humans, but computer systems that parse 
the FML text into elemental attributes and data fields that are further processed. 
On the basis of this technical background about 30 message types are defined, including 
preliminary requests and patient updates, search results, typing requests and results, sample 
requests, notification of sample arrival date and sample testing results, IDM (Infectious disease 
markers) requests and results, donor reservation requests and results, workup requests and results, 
etc. 
The most advanced feature in EMDIS is the donor search process. When a national registry 
initiates an international donor search for a specific patient, its data is broadcasted to other EMDIS 
registries. Every recipient (i.e. computer system) makes a donor search in the local database using its 
own algorithm and technology and replies with a set of potential donors. Then the requesting 
registry composes these partial results into one global EMDIS search result. In praxis, these results 
are received within several hours.  
After this procedure, the patient is in the “Preliminary status” and no further action is taken. 
But the local registry can change this status to “Active” by broadcasting the Patient status change 
message to other registries. The preliminary search result could be outdated after a few days. If the 
patient is in the Active status, every remote registry runs a regular repeat search process for this 
patient and checks if the search result has changed. The differential update is sent back to the 
patient’s registry. It could contain new and better donors than previously reported or other changes 
in the current search result. 
Finally, when the patient case is closed, the national registry broadcasts the Patient status 
change message with the new status “Stopped” and the repeat search process of this patient is 
ended. 
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Figure 58: EMDIS communication. HUB is a national stem cell donor registry.  
 
C.2 Software Implementation 
The basic components of the EMDIS software include: 
1. An email system to send and receive messages 
2. Software based on ECS (EMDIS Communication System) rules to control the sending and 
receipt of messages 
3. Software to encrypt and decrypt messages 
4. Software to validate the EMDIS FML message (the FML parser). FML = Flexible Mesage 
Language. 
5. Functions to interpret process and respond to messages – EMDIS message processor. 
6. Search engine to run preliminary and repeat searches 
7. User interface to create and manage EMDIS messages 
 
The first four components exist outside of the registry software and are currently available free 
of charge. The four form a package called ESTER (ECS message Transfer between EMDIS Registries) 
(http://www.steinersw.eu/en/ester.html), also commonly known as middleware,. ESTER uses the 
FML parser developed by ZKRD. ESTER runs under the Windows operating system. 
A platform independent implementation of the first three components is called PerlECS, which 
was developed by NMDP. 
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Figure 59: EMDIS Implementation of the British Bone Marrow Donor Registry. 
 
The fifth, sixth and seventh components, the EMDIS message processor, search engine and 
user interface, are the most complex ones. They are available as separate piece of software, known 
as Prometheus, required linking ESTER to a copy of the local registry database. 
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EMDIS implementation can vary from one registry to another. Typically, a registry receives a 
search or sample request from its own national or regional transplant centre by e-mail or fax. These 
are then passed via EMDIS to all of the active EMDIS nodes. Responses to these requests are sent 
back from the external EMDIS nodes and then relayed by some other means to the originating 
transplant centre.  This is patient-related EMDIS messaging. 
If the local system implements the original idea of a ‘single virtual international registry’, it 
must maintain the same status of the patient in all EMDIS registries. And this could include the 
national registry itself. Then there is no difference between a local and a remote search, it is only an 
EMDIS search. The advantage is that the local system also notifies changes of search result as it does 
for foreign patients. 
The registry can also receive and respond to search or sample requests from other registries 
directly via EMDIS. This is donor-related EMDIS messaging. 
Not all registries have chosen, or are able, to respond to all of the available EMDIS messages 
and some registries process donor-related messages only. 
C.3 EMDIS Governance 
Bidirectional messaging between registries follows highly structured protocols and standard 
nomenclature agreed and controlled by the EMDIS community.  
The EMDIS organizational structure and rules are described by EMDIS House Rules and reflect 
the procedures of a working party with a high level of user involvement and a focus on practical 
issues.  
EMDIS User Group coordinates the advancement of EMDIS to achieve the goals of the 
network; sanctions and approves new EMDIS Users; validates and prioritises User needs; liaises with 
the Technical Group over specifications, time-tables and feasibility of requirements. 
EMDIS Technical Group protects the integrity of the EMDIS system, technology and 
infrastructure; defines technical requirements for the participation in EMDIS, defines interfacing 
rules and prepares the necessary documentation; reviews proposals for new developments 
emanating from the User Group; prepares specifications and timetables for implementation by 
national development teams; liaises with the User Group and the national development teams of the 
member registries. 
These groups meets regularly to discuss requests for change and to oversee the 
implementation of new versions of EMDIS. General maintenance, training and operational issues are 
also supported by the WMDA IT Working Group. 
EMDIS membership is open to unrelated donor registries that actively use the EMDIS system 
(EMDIS hubs). Membership application has to be submitted to the chair of the EMDIS User Group for 
review and be approved by the EMDIS User Group.  
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Appendix D: Comparison of HFE programs 
 
 CZ (Czech republic, 
this work) 
ZKRD (Germany) DKMS (Germany) FGM (France) ANT (UK) Europdonor 
(Netherlands) 
NMDP (USA) 
Program name Prometheus HFE OptiHapfreq Haplomat Estihaplo Cactus Haplo3v5.exe NA 
Language(s) Embarcadero 
Delphi 2007 
Perl and C Perl C++ Perl and C Visual Basic 6.0 perl 
Platform Windows Linux/MAC Windows/Linux Windows/Linux/MAC Linux/MAC Windows Windows/Linux/MAC 
Max # loci/alleles 5/None None 6/none None None 3/2000 none 
# limit of 
phenotypes/individual 
for serology/low res 
Theoretically no 
limit, but 
practically, 4.1 
million individuals. 
No Yes, not used for 
high resolution 
haplotype 
inference 
No No No Only if estimating 
high res haplotype 
freqs 
# limit of 
phenotypes/individual 
for high res 
same No Yes, hardware 
limitations at large 
numbers (>1 
million) 
No No No No 
Accepted Input  Serology, 
Nomenclature v2, 
v3, NMDP allele 
codes 
Serology, 
Nomenclature v2, 
v3, NMDP allele 
codes, genotypes 
lists 
Serology, 
Nomenclature v3, 
NMDP allele codes, 
genotypes lists 
Serology, 
Nomenclature v2, 
v3, NMDP allele 
codes 
Nomenclature v2 Serology, 
Nomenclature v2, 
v3 
Serology, 
Nomenclature v2, 
v3, NMDP allele 
codes, genotypes 
lists 
Alleles abbreviated to 
2 fields 
yes Optional Yes No Optional No Optional 
Alleles mapped to p- optional Optional Yes No no no Optional 
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like groups 
Ambiguities DNA, missing loci Serologic, DNA, 
missing loci, null 
antigen/allele 
DNA, missing loci, 
null antigen/allele 
(only in antigen 
level setting for 
DRB1) 
Serologic, DNA, 
missing loci, null 
antigen/allele 
Serologic, DNA, 
missing loci 
None Serologic, DNA, 
missing loci, null 
antigen/allele 
Method to handle 
ambiguities 
All possible 
genotypes are 
considered. 
Consider all 
possibilities 
If “p-identical” 
over exon 2/3 
including nulls then 
merged to “g”-
nomenclature. [69] 
 
If SBT typing 
ambiguities, then 
include all possible 
combinations 
(According to 
IMGT/HLA Release 
number in use). If 
intermediate 
resolution typing 
results, then 
include all possible 
combinations. 
Missing data: 
Include all possible 
combinations. 
Consider all possible 
diplotypes 
combinations 
Expanding 
diplotypes 
generated by 
phenotypes with 
missing/ambiguous 
typing and let EM 
process them 
Remove from 
records 
Consider all 
possibilities 
EM with HWE yes Yes Yes Yes Yes No Yes 
Starting values Equal, user-
defined, at 
Equal, user-defind, 
at random, based 
user-defined, 
simulated 
user-defined, at 
random, simulated 
Equal, at random, 
based on allele-
Equal Equal, user-defined, 
at random, based on 
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random, based on 
allele-frequencies 
on allele-
frequencies 
distribution distribution frequencies allele-frequencies 
Terminating criteria Based on likelihood 
change, # 
iterations 
Based on 
frequency change 
Based on 
frequency change 
Based on frequency 
change 
Based on likelihood 
change, # 
iterations 
Based on 
frequency change, 
# iterations 
Based on frequency 
change 
Terminating threshold Specified by user: 
0.00001 
Specified by user: 
1E
-6
 likelihood 
changed between 
iterations 
Fixed. value used 
in task 1: 
Sum(Abs(diff(fn-
fn+1)))<1e-5 
value used in task 
2 Max(Abs(diff(fn-
fn+1)))<1e-6 
Specified by user: 



1tt  
Specified by user: 
1E
-6
 likelihood 
changed between 
iterations 
Specified by user: 
2048 iterations for 
tasks 1 and 2 
Specified by user: 1E
-
6
 likelihood changed 
between iterations 
Handling low 
frequency haplotypes 
low frequency 
haplotypes are 
excluded, 
threshold = 
1/(2xSample_size) 
Iterative tail 
truncation as long 
as LLH increases 
No special handling No skimming – 
output is optional 
No special handling Mathematically no 
problem, values of 
4.3E
-310
 might be 
observed 
Haplotypes with 
count < 0.01 are not 
reported 
Key features Output loci and 
resolution could be 
customized: 
serology broad, 
serology split, DNA 
low res, DNA high 
res. 
 High resolution 
haplotype 
frequency 
inference from 
intermediate to 
high resolution 
HLA typing results. 
Antigen resolution 
typing results are 
used exclusively 
for antigen 
resolution 
haplotype 
 Developed as a 
perl module. Main 
script is coded 
using module 
EM implemented 
by iterating the 
probabilities of 
discretion of 
phenotypes 
- 2-locus + 3-locus LD 
- Standard error 
- Allele frequency 
and 2-locus 
haplotype tables 
- HW exact test 
- Wn statistic 
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inference only 
Output format Floating point Fixed point (10 
digits) 
Floating point Fixed point : 6 digit Floating point Fixed point (14 
digits), floating 
point 
Floating point 
Task 1 running 
time/CPU/memory 
Standard PC, 
Windows XP, 1 
processor, 4GB 
RAM. less than one 
hour 
 10.5h  CPU 4 
memory 7.9 GB 
<24h 6m 45s/2.4 
GHz/140MB 
Typical input 8 
million A, B, DR low 
res BMDW 
individuals in 12 
hours running time 
on PC 
< 1 day / 2 Intel Xeon 
X5690 6-core 3.47 
GHz / 100 GB 
Task 2 running 
time/CPU/memory 
Same/15 hours 40 hrs 4 days  CPU 12 
memory 192 GB 
<24h 0-20: 2h 45m/3 
GHZ/850 MB 
20-60: 18m 40s/3 
GHZ/470 MB 
 Same 
Table 33: Characteristics of the seven HFE computer programs. 
 
